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Affecting close to 6 million people in the United States, heart failure (HF) 
represents the final stage of several diseases of the heart and is commonly defined as a 
reduction in the heart’s ability to circulate blood. Cardiac output during right heart 
catheterization is an important variable used in patient selection for advanced therapies, 
such as cardiac transplantation and left ventricular assist device implantation. It is 
common practice to utilize the Fick method to determine the cardiac output (cardiac 
output = oxygen consumption [VO2]/arteriovenous oxygen difference) inputting 
estimated VO2 from one of three published empirical formulae. However, these 
estimation equations have not been validated in patients with HF. The purpose of this 
study was to determine the accuracy of three widely used equations for the estimation of 
VO2 compared to direct breath-by-breath measurement of VO2 and determine to what 
extent clinically significant error occurs in patients with HF and reduced ejection fraction 
(HFrEF).  
Forty-four patients with HFrEF undergoing routine cardiac catheterization (65.9% 
male, 65.9% Caucasian, 64.5 + 10.7 years old) performed 10 minutes of ventilatory gas 
exchange immediately following catheterization procedures, and averaged results of the 
last five minutes were compared to the derived estimations by: LaFarge & Miettinen, 
Dehmer et al. and Bergstra et al. (estimated – measured). Single-sample t-tests found the 
mean difference between the estimation of LaFarge & Miettinen was not significant (-
 
10.3 ml/min + 6.2 SE, p=0.053), but significant differences were found with Dehmer et 
al. (16.0 ml/min + 6.4 SE, p=0.008) and Bergstra et al. (40.6 ml/min + 6.4 SE, p<0.001). 
Bland-Altman plots demonstrated limits of agreement outside of acceptable limits with 
trends towards overestimation in patients with low VO2 and underestimation in patients 
with higher VO2 for all equations. Bland-Altman plots and single-sample t-tests of 
dichotomous groups (sex, pulmonary hypertension and aldosterone antagonist 
medication) did not identify a subgroup where any of the equations were acceptable. The 
rate of >25% error in the estimates of the LaFarge & Miettinen, Dehmer et al. and 
Bergstra et al. equations occurred in 11%, 23% and 45% (respectively) of the patients. 
Clinically significant error (misclassification) in the cardiac index derived from the 
Lafarge & Miettinen, Dehmer et al. and Bergstra et al. equations for three clinically 
important classifications: cardiogenic shock – 20.5%, 22.7% and 31.8%; hypoperfusion – 
15.9%, 15.9% and 25%; abnormal – 13.6%, 13.6% and 15.9%, respectively. Exploring 
possible HFrEF-specific equations, linear regression modeling was performed with 34 
patients. Two models were developed: (Model 1) VO2=-10.76+(127.74*body surface 
area)+(aldosterone antagonist [prescribed=1, not prescribed=-1]*22.15); (Model 2) 
VO2=149.4+(sex [male=1, female=-1]*25.41)+(aldosterone antagonist [prescribed=1, 
not prescribed=-1]*28.34). Bland-Altman plots and t-tests with the remaining 10 patients 
yielded limits of agreement outside of acceptable limits despite lack of significant 
differences between the estimated and measured VO2 for Model 1 and Model 2 (11.0 
ml/min + 10.7 SE, p=0.165; 12.4 ml/min + 0.249, p=0.249). These findings do not 
support the use of these empirical formulae to estimate the resting VO2 in patients with 
 
HFrEF undergoing right heart catheterization. The direct measurement of the resting VO2 
should be the primary method applied to the Fick equation for cardiac output. 
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CHAPTER I 
 
INTRODUCTION 
 
 
Heart failure (HF) is a complex syndrome resulting from any structural or 
functional disorder that limits the ability of a ventricle to contract (most commonly 
associated with the left ventricle) and eject blood [HF with a reduced left ventricular 
ejection fraction (LVEF), or HFrEF] or relax and fill with blood [HF with preserved 
LVEF (HFpEF)], and represents the severest stage of several disorders/diseases of the 
heart (Bui, Horwich, & Fonarow, 2011; Hunt et al., 2009; Lindenfeld et al., 2010). In 
physiological terms, the Heart Failure Society of America describes HF as the presence 
of elevated cardiac filling pressure (typical finding of HFpEF) and/or inadequate oxygen 
(O2) delivery to the periphery (typical finding of HFrEF), either at rest or during stress, 
that is caused by a cardiac dysfunction (Lindenfeld et al., 2010). As the HF syndrome 
advances in those (initially) with HFpEF, reductions in LVEF below 45% will occur and 
will then be considered to have HFrEF. 
In the United States HF (HFpEF and HFrEF) represents a major health problem, 
with a prevalence of approximately 2.4% of the population, or about 5.7 million people 
(Roger et al., 2012). The prevalence in those > 70 years old is approximately 20% (Roger 
et al., 2012). Annually, about 550,000 new cases of HF are diagnosed each year, and 
there is roughly a 1 in 5 lifetime risk of developing HF in the United States (Levy et al., 
2002; Lloyd-Jones et al., 2010). There are nearly 300,000 deaths per year attributable to 
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HF, with annual healthcare cost estimations reaching $39 billion in 2010 when the cost of 
hospitalizations, medications and loss of productivity are considered (Bui et al., 2011). 
Cardiac output (while supine at rest) is an important measure in the determination 
of HF severity and in assessment of the need for advanced therapies (cardiac transplant or 
left ventricular assist device (LVAD)). Furthermore, cardiac index (cardiac output/body 
surface area (BSA)) is a more sensitive indicator of the heart’s ability to perfuse all the 
body’s tissues. For example, if two patients have the same cardiac output of 5 L/min, but 
one patient has a BSA of 1.79 m2 and the other has a BSA of 2.22 m2, the first patient 
then has a cardiac index of 2.8 L/min/m2, where the second patient has a cardiac index of 
only 2.2 L/min/m2. A cardiac index <2.2 L/min/m2 is an indicator for advanced therapies 
in patients with HFrEF. However, a very low cardiac index (<1.9 L/min/m2) represents a 
state of shock and is associated with poor outcomes when considering LVAD 
implantation as advanced therapy (Ginsberg & Parrillo, 2009; Kirklin et al., 2010; 
Slaughter et al., 2010). Thus, it is possible that an error as little as 14% in the measure of 
cardiac index can have significant influence on the patient’s disease management. 
Though the cardiac index may be a more sensitive indicator of the heart’s 
perfusion performance, the absolute cardiac output is an important variable in the 
calculation of a number of other derived variables, such as, systemic and pulmonary 
vascular resistance, total pulmonary resistance, valvular orifice area, and right ventricular 
stroke work index. All of these variables are used to assist in guiding care and treatment 
of patients with HFrEF (Lindenfeld et al., 2010) and are strong prognostic indicators of 
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poor outcomes after cardiac transplant or LVAD procedures (Kirklin et al., 2010; Mehra 
et al., 2006; Slaughter et al., 2010). 
Cardiac output is typically measured during catheterization of the right side of the 
heart. The most common determination of cardiac output during a right heart 
catheterization is by the thermal dilution method. This method involves injecting a 
known volume of cooled saline into the right atrial blood flow, which is then measured 
distally in the right ventricular outflow tract. The change in temperature is related to the 
flow of blood. Another common method to estimate cardiac output is by the Fick method, 
which (by formula) states that cardiac output is equal to the rate of O2 consumption 
(VO2) divided by the O2 content difference of the arterial and venous blood (a-vO2Diff). 
Considering the history of measuring cardiac output, the Fick principle is the “Gold 
Standard” as it was used to validate other measures, such as thermal dilution. 
Furthermore, there are several conditions which can cause erroneous cardiac output 
results with the thermal dilution method that justify the measurement of cardiac output by 
the Fick method. All of these conditions potentially cause the cooled fluid greater 
opportunity to have contact with the chamber walls of the right atrium and ventricle 
effectively warming the fluid above what blood alone would do, which causes an 
overestimation of cardiac output (Baim & Grossman, 2006; van Grondelle, Ditchey, 
Groves, Wagner, & Reeves, 1983). These conditions include atrial dysrhythmias, 
tricuspid valve regurgitation, ventricular dyssynchrony, and low output states (absolute 
cardiac output <3.5 L/min) (Kendrick, West, Papouchado, & Rozkovec, 1988). Though 
the low output is the most common of these conditions in patients with HFrEF (Cotter et 
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al., 2003), these patients are at higher risk of developing any of these conditions. 
Therefore, it is common practice for physicians performing cardiac output measurements 
in patients with HFrEF to utilize the Fick method for measuring cardiac output. 
 Proper measurement of resting cardiac output by the Fick method requires the 
measurement of VO2 and gas analysis of arterial and mixed venous blood. It has become 
common practice to estimate the patient’s resting VO2 utilizing one of three common 
equations (Narang et al., 2012). All of these assume a constant resting VO2 based on a set 
of patient characteristics. As an example, the most common is simply 125xBSA 
(Dehmer, Firth, & Hillis, 1982), which suggests that the resting VO2 of an individual is 
based solely on the patient’s estimated BSA. Other proposed formulas, attempt to 
individualize beyond BSA by including age, sex and/or heart rate into the estimation 
(Bergstra, van Dijk, Hillege, Lie, & Mook, 1995; LaFarge & Miettinen, 1970). Despite 
these equations being widely used on patients with HFrEF, a review of the literature 
indicates that the three most commonly used estimations have not been well validated 
with patients with HFrEF. Therefore, the purpose of this study was to measure the resting 
VO2 in adult patients with HFrEF during right heart catheterization procedures, 
investigate the accuracy of three widely used equations for the estimation of resting VO2 
compared to the direct breath-by-breath measurement of expired air using a metabolic 
cart and determine to what extent clinically significant errors occur using estimation 
equations. 
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Statement of Problem 
It is widely accepted that the Fick method of measuring cardiac output is the most 
reliable method in patients with HFrEF, which relies on the measurement of VO2. 
However, it is normal practice to estimate resting VO2 in order to calculate the cardiac 
output via the Fick method utilizing one of three popular estimation equations. 
Unfortunately, these equations have been derived from selected cohorts that have 
included very few, if any, patients with HFrEF. Thus, the validity of these equations is 
unknown in patients with HFrEF undergoing right heart catheterization. 
Purpose of the Study 
The purpose of this study was to measure the resting VO2 in adult patients with 
HFrEF during right heart catheterization procedures, investigate the accuracy of three 
widely used equations for the estimation of resting VO2 compared to the direct breath-by-
breath measurement of expired air using a metabolic cart and determine to what extent 
clinically significant errors occur using estimation equations. 
Aims & Hypotheses 
This study was designed to: 
1) Compare the difference between the measured resting VO2 and estimates from 
each of three commonly used formulas (LaFarge & Miettinen, 1970; Dehmer et 
al., 1982; and Bergstra et al., 1995): 
a. Primary Aim – The difference between measured and estimated VO2 was 
evaluated for the whole sample. 
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Hypothesis:  The differences between measured VO2 and the three 
estimations will each be statistically significant. 
b.  Secondary Aim (exploratory) - The difference between measured and 
estimated was evaluated for select grouping variables (e.g., sex, sedation, 
and etiology). Variables that were found to have a significant effect on 
resting VO2 were entered as covariates when comparing measured and 
estimated VO2. 
Hypothesis: While some variables may improve the comparison between 
measured versus estimated VO2 and others may make no difference, it is 
expected that the differences will remain statistically significant.  
2)  Determine if the differences between the measured resting VO2 and the VO2 
estimated by each of the commonly used formulas are clinically significant. 
 a.  Primary Aim - Determined the frequency of >25% absolute error in the 
resting VO2 derived by the three estimations. 
Hypothesis:  Clinically significant errors will be found in >15% of the 
patients studied for each of the three estimation equations. 
b. Secondary Aim - Determined the sensitivity and specificity of correctly 
classifying the cardiac index by each of the estimation equations at the 
following cut-off values: </> 2.6 ml/min/m2 (low versus normal cardiac 
index), </> 2.2 ml/min/m2 (hypoperfusion versus no hypoperfusion), </> 
1.9 (cardiogenic shock versus no shock). 
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Hypothesis: At each level of cut-off, >15% of patients will be 
misclassified by each of the estimation equations.  
3) If the Aim 1 hypothesis holds true for all three estimation equations, then an 
estimation formula will be derived from the measured resting VO2 combined with 
select clinical variables.  
Hypothesis:  Though exploratory in nature, the estimation equation can be 
developed and will include variables beyond what is employed by the 
three estimation equations being tested.    
Study Impact 
Whether the above hypotheses hold true or not, this study will provide data to 
physicians that may help form decisions concerning appropriate clinical treatment. 
However, if the proposed hypotheses hold true, then the study will influence the current 
methods used to measure cardiac output in patients HFrEF. However, if the hypotheses 
are not supported, the study will remain an important contribution to the literature 
validating the use of these equations in patients with HFrEF.  
Delimitations 
1) The participants in this study were adult patients (>18 years old at time of 
consent) with HFrEF undergoing clinically indicated right heart catheterization. 
2) Patients had resting VO2 measured with breath-by-breath analysis via a metabolic 
cart while breathing through mouthpiece in a similar fashion as LaFarge & 
Miettinen (LaFarge & Miettinen, 1970), and others who have re-evaluated these 
formulas in different patient groups (Fakler, Pauli, Hennig, Sebening, & Hess, 
7 
 
2005; Kendrick et al., 1988; Narang et al., 2012; Narang et al., 2014; Wolf, 
Pollman, Trindade, Fowler, & Alderman, 1998).   
3) Sedation was used in the development of the three equations in question (Bergstra 
et al., 1995; Dehmer et al., 1982; LaFarge & Miettinen, 1970). Therefore, patients 
were given (operating physicians discretion) no more than standard sedation for 
the catheterization procedure (not to exceed 2 mg of midazolam and/or 50 µg of 
fentanyl). 
Limitations 
1) Patients are generally not accustomed to having breathing monitored, particularly 
while breathing through a mouthpiece. This may have inherently changed the 
patient’s breathing characteristics and influence resting VO2 (Perez & Tobin, 
1985). However, this is a common method for measuring ventilatory gas 
exchange and was the method utilized be LaFarge & Miettinen (LaFarge & 
Miettinen, 1970). 
2) Gas exchange was measured breath-by-breath with a metabolic cart (Ultima-CPX, 
MGC Diagnostics Corp., St. Paul, MN). This is a different method of collecting 
and measuring ventilation and gas exchange than that performed by LaFarge & 
Miettinen. Although this may have limited the comparison, this method of 
measuring gas exchange (compared to Douglas bag method used by LaFarge & 
Miettinen) is more common in modern laboratories, making it more clinically 
applicable.   
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3) Due to the limitation of the system available to measure the resting VO2, the 
measurement of gas exchange was not possible while the patient is receiving 
supplemental O2. Therefore, if the patient (who is otherwise not prescribed home 
supplemental O2) was expected to need supplemental O2 after receiving sedation 
were excluded.  
4) Most of the study participants were partially sedated during VO2 measurement. 
Sedation given to patients prior to catheterization can vary between patients and 
the patient may need additional sedation during the case. For the safety of the 
patient, the exact dose was left to physician discretion. The level of sedation can 
influence the patient’s ability to maintain an appropriate seal on the mouthpiece. 
This problem was minimized through constant observation and appropriate 
coaching by the primary investigator. In addition, the exact dose of sedation was 
recorded and patients receiving greater than the standard dosing were excluded 
from this study.  
5) The proposed sample size was sufficiently powered to compare the measured 
versus the estimated resting VO2 in the whole sample, similar to previous studies 
evaluating these estimation equations. However, this sample size is likely too 
small to evaluate the sex-specific aspects for the formulas of LaFarge & Miettinen 
and Bergstra et al. This, along with other comparisons, was included as part of the 
analysis for the secondary aim to Aim 1. 
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Definitions of Terms 
1) Basal Metabolism – The minimum amount of energy required to maintain vital 
functions at complete rest while in a fasting state. 
2) Body Surface Area (BSA) – The area of the external surface of the body. Being 
difficult to accurately measure directly, BSA is commonly estimated using one of 
several equations that utilize height and weight measurements. Although 
developed from only 9 individuals, the formula derived by Du Bois and Du Bois 
in 1916 has been shown to be surprisingly accurate and remains the most widely 
used estimation of BSA. (Wang, Moss, & Thisted, 1992)  
3) Cardiac Index –Cardiac output per unit of body surface area. Cardiac index relates 
cardiac performance to the size of the individual. The normal range at rest is 2.6 
to 4.2 ml/min/m2 (Brandfonbrener, Landowne, & Shock, 1955). 
4) Cardiac Output – The volume of blood being pumped by the heart per minute. 
Cardiac output is the product of the heart rate and stroke volume. 
5) Cardiomyopathy – A disorder causing structural or functional limitation of the 
ventricle (Lindenfeld et al., 2010) 
a. Ischemic Cardiomyopathy (ICM) – Identifies the antecedent cause of the 
cardiomyopathy as the result of ischemia induced by a myocardial infarct 
(MI). 
b. Non-Ischemic Cardiomyopathy (NICM) – Identifies the antecedent cause 
of the cardiomyopathy as something other than an MI (i.e., hypertension, 
viral, peri-/post-partum, genetic, idiopathic, etc.).  
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6) Ejection Fraction – A measure the fraction of blood squeezed out of a ventricle 
with every beat, commonly reported as a percentage. Mathematically, it is the 
volume of blood left in the ventricle at the end of systole (End Systolic Volume) 
divided by the volume of blood in the ventricle at the end of diastole (End 
Diastolic Volume). Both left ventricular (LVEF) and right ventricular (RVEF) 
ejection fractions can be assessed. 
7) Fick Principle – Proposed by Adolph Fick in 1870 as a method for measuring 
cardiac output in vivo, it is based on the law of conservation of mass/energy and 
states that the cardiac output is proportional to the VO2 divided by the difference 
in O2 concentration between the atrial and mixed venous blood (Baim & 
Grossman, 2006). 
8) Heart Failure (HF) – A complex syndrome, representing a common final stage of 
many different disorders of the heart, which results from any structural or 
functional disorder that limits the ability of a ventricle to relax and fill with blood 
and/or contract and eject blood (Bui et al., 2011; Dickstein et al., 2008; Hunt et 
al., 2009).  This cardiac dysfunction leads to neurohormonal and circulatory 
abnormalities which cause characteristic signs and symptoms such as fluid 
retention, shortness of breath and fatigue – particularly with exertion (Lindenfeld 
et al., 2010). Physiologically, it is characterized by increased cardiac filling 
pressure and/or insufficient peripheral O2 delivery (Lindenfeld et al., 2010). 
a. HF with Reduced Left Ventricular Ejection Fraction (HFrEF) – Also 
referred to as HF with dilated left ventricle, it is a categorization of HF 
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that is characterized by a reduced LVEF and is most commonly associated 
with left ventricular chamber dilation (Lindenfeld et al., 2010). 
b. HF with Preserved Left Ventricular Ejection Fraction (HFpEF) – Also 
referred to as diastolic HF, it is a categorization of HF that is characterized 
by normal LVEF and is often associated with incomplete or abnormal 
relaxation during diastole (Lindenfeld et al., 2010). 
9)  Heart Transplant – A surgical procedure performed on patients with end-stage 
HF, where a functioning heart from a recently deceased donor is implanted into 
the recipient patient. Most commonly, the recipient patient's heart is removed 
(orthotopic). Alternatively (and much less common), the recipient’s heart may be 
left in to support the donor heart (heterotopic). Five year graft survival was 75% 
in patients receiving transplants in 2005-2006, and there has been a steady decline 
in rate of 10-year graft failure (Organ Procurement and Transplantation Network 
& Scientific Registry of Transplant Recipients, 2012). 
10) Resting Metabolism or Resting Energy Expenditure – The amount of energy 
required while an individual is at rest and typically not in a fasted state. This value 
is usually slightly higher than the individual’s basal metabolism and frequently 
used as an estimation of true basal metabolism. 
11) Right Heart Catheterization – A minimally invasive diagnostic procedure in 
which a catheter is guided though the right side of the heart and into the 
pulmonary artery where the heart’s pump function and pressures within the heart 
and pulmonary arteries can be assessed (Baim & Grossman, 2006).  
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12) Stroke Volume (SV) – The volume of blood ejected from the heart with every 
beat.  
13) Thermal Dilution Method – A common indicator dilution method for measuring 
cardiac output during a right heart catheterization where an injected bolus of 
chilled sterile solution in the right atrium mixes with the blood and passes through 
the tricuspid valve into the right ventricle. A thermistor at the distal end of the 
catheter measures the change in blood temperature as the blood passes over the 
catheter tip (Baim & Grossman, 2006).  Similar to the Fick method, this method is 
based on the law of conservation of mass/energy.  
14) Ventricular Assist Device (VAD) – A surgically implanted device that helps the 
heart pump blood from one (left is most common [LVAD]) or both (BiVAD) 
ventricles. These pumps may be implanted in the body or connected to a pump 
outside the body. Frequently, used as a bridge to transplant, but increasingly used 
as destination therapy in those with end-stage HF who do not qualify for a heart 
transplant. 
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CHAPTER II 
REVIEW OF LITERATURE 
The purpose of this study was to measure the resting VO2 in adult patients with 
HFrEF during right heart catheterization procedures, investigate the accuracy of three 
widely used equations for the estimation of resting VO2 compared to the direct breath-by-
breath measurement of expired air using a metabolic cart and determine to what extent 
clinically significant errors occur using estimation equations.  
This chapter discusses the literature reviewed in relation to this topic. The chapter 
provides information regarding HF, including the epidemiology of the syndrome and its 
medical and surgical treatment. Furthermore, this chapter discusses in detail the right 
heart catheterization procedure, cardiac output and how it is determined by the thermal 
dilution and Fick methods. Then, why the Fick method of determining cardiac output is 
preferred in patients with HF is discussed. Lastly, the determination of resting VO2 (a 
critical value for determining cardiac output by the Fick method) by direct analysis of 
ventilatory gas exchange and by the three most popular estimation equations is reviewed.  
Heart Failure 
Heart failure is a complex clinical syndrome with many potential etiologies, and 
is characterized by elevated mortality, reduced quality of life, frequent hospitalizations 
and complex medical management (Heart Failure Society Of America, 2006). Heart 
failure has a high prevalence in the United States and elsewhere, and for most patients it 
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is a chronic condition. The prevalence of HF is growing due to the aging population and 
better treatment of antecedent conditions (Bui et al., 2011; Heart Failure Society Of 
America, 2006). In fact, as part of the Affordable Care Act, the Centers for Medicare and 
Medicaid Services have begun to penalize hospitals with excessive 30-day re-admission 
rates for patients admitted with heart attack, HF and pneumonia (Ross, Bernheim, & 
Drye, 2011). The Centers for Medicare and Medicaid Services has recognized that re-
admission rates are too high in these three categories and has determined these conditions 
as reflective of the treatment of Medicare/Medicaid patients (Ross et al., 2011). Current 
medical therapy with angiotensin-converting enzyme inhibitor (ACEI), beta-receptor 
blockade and diuretics can provide reductions or delays in morbid events, and may even 
lead to some reversal of cardiac remodeling (Heart Failure Society Of America, 2006). 
Nevertheless, there remains no absolute cure for HF short of cardiac transplantation. 
Epidemiology and Definition of Heart Failure: 
Heart failure is a significant public health problem in the United States and the 
world over. Prevalence of HF in the United States is approximately 2.4% of the 
population or about 5.8 million people, while the prevalence in those > 70 years old is 
approximately 20% (Roger et al., 2012). Data suggests the incidence of HF of roughly 
670,000 new cases per year (Levy et al., 2002; Roger et al., 2012). In adults over the age 
of 45, the lifetime risk of developing HF is approximately 25% (slightly higher in men 
than women), and approaches 40% in people aged 65 and older (Huffman et al., 2013).  
Though limited by healthcare disparities and more advanced disease at first 
diagnosis, the data indicates that minorities have higher incidence of HFrEF than whites 
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(Yancy, 2004). Data from the Multi-Ethnic Study of Atherosclerosis (MESA), a 
prospective cohort study, reports 75% of incidence of HF among African Americans was 
due to HFrEF, compared to 58% in Hispanics and 60% whites - the latter two showing a 
non-significant difference (Bahrami et al., 2008). There are significant incidence rate 
differences between African American, Hispanics and whites: 3.5, 2.1 and 1.5 per 1000 
person-years, respectively (Bahrami et al., 2008). In a fairly comprehensive analysis of 
large population studies found that the unadjusted risk in black men to be highest, and at 
a lower age than other sex-race groups (Huffman et al., 2013). Interestingly, black men 
were found to have a lower lifetime risk at age 45 than their white male counterparts 
(20% vs 30%), which appeared to be related to competing risks of death from non-
cardiovascular causes (Huffman et al., 2013). 
Due to a wide number and varied causes, HF without an antecedent myocardial 
infarction causing cardiac muscle dysfunction (sometimes referred to as non-ischemic 
cardiomyopathy, or NICM) is the most common. In American adults, prevalence of 
NICM is 36 per 100,000 people and incidence is 5.5 per 100,000 people (Towbin et al., 
2006). In adults over the age of 40, the lifetime risk of developing HF due to NICM is 1 
in 9 for men and 1 in 6 for women (Roger et al., 2012). Making up a large cohort of the 
5.8 million people with HF in the United States, NICM is the most common reason for 
heart transplant, with an annual care-cost ranging from $4 billion to $10 billion (Roger et 
al., 2012; Towbin et al., 2006).  
It is estimated that an additional 3 million people will have HF by 2030, which 
represent roughly a 25% increase in the prevalence of HF (Roger et al., 2012). Heart 
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failure may be the fastest growing cardiovascular disease. For example, between 1979 
and 2003 there was a 174% increase in hospitalizations for HF compared to a 16% 
increase in coronary artery disease (CAD) admissions and 29% increase in admissions 
due to stroke (Mensah & Brown, 2007). Furthermore, HF has consistently been one of 
the major cardiovascular disease indications for outpatient office visits and emergency 
department admissions, second only to hypertension (Mensah & Brown, 2007; O'Connell 
& Bristow, 1994). When combining the cost of health-care services, medications and lost 
productivity, the estimated cost of HF exceeded $39 billion in 2010 (Lloyd-Jones et al., 
2010; Roger et al., 2012). It is thought that this cost is actually under-estimated as it is 
based on data with HF as the primary diagnosis or cause of death (Bui et al., 2011).  
Heart failure is a complex syndrome representing a common final stage of many 
different disorders of the heart (Bui et al., 2011). The American Heart Association and 
the American College of Cardiology, as well as the European Society of Cardiology, 
define HF as a complex syndrome resulting from any structural or functional disorder 
that limits the ability of the left ventricle to relax and fill with blood (diastole) and/or 
contract and eject blood (systole) (Dickstein et al., 2008; Hunt et al., 2009). The 
underlying disorder causing the structural or functional limitation of the ventricle that 
leads to HF is referred to as a cardiomyopathy. Symptoms of cardiomyopathies include: 
shortness of breath, fatigue and/or exercise intolerance (Dickstein et al., 2008; Hunt et al., 
2009). In distinguishing between cardiomyopathy and HF additional signs and symptoms 
of fluid retention must be present (Dickstein et al., 2008; Hunt et al., 2009). The 2008 
guidelines from the European Society of Cardiology suggest that an improvement in 
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response to typical HF treatment is not sufficient to make the diagnosis of HF, but can be 
helpful when a clear diagnosis is unclear (Dickstein et al., 2008). The definition used by 
these entities makes the diagnosis of HF more practical, but are somewhat broad. In the 
last several publications of practice guidelines from the Heart Failure Society of America, 
the definition of HF has been called a “working” definition (Heart Failure Society Of 
America, 2006; Lindenfeld et al., 2010). This implies the definition is evolving, and is 
tied to the continued and developing understanding of this syndrome. As defined by the 
Heart Failure Society of America, HF is a syndrome resulting from cardiac dysfunction 
(cardiomyopathy), which leads to neurohormonal and circulatory abnormalities that lead 
to the characteristic signs and symptoms such as fluid retention, shortness of breath and 
fatigue - particularly with exertion (Lindenfeld et al., 2010). Physiologically, the Heart 
Failure Society of America describes the syndrome as being characterized by increased 
cardiac filling pressures and/or insufficient peripheral O2 delivery caused by a 
cardiomyopathy (Lindenfeld et al., 2010).  
Expanding the definition further, the 2010 Heart Failure Society of America 
practice guidelines categorize HF as with either a reduced left ventricular ejection 
fraction (HFrEF) or a preserved left ventricular ejection fraction (HFpEF) (Lindenfeld et 
al., 2010). More commonly thought of when the term HF is used, HFrEF (also referred to 
as HF with dilated left ventricle) is characterized by signs and symptoms of HF and is 
most commonly associated with left ventricular chamber dilation (Lindenfeld et al., 
2010). The reduced LVEF can be thought of as being a result in reduced squeezing of the 
heart muscle during systole. So, it is still common to see this referred to as systolic HF. 
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On the other hand, with HFpEF, the signs and symptoms of HF can exist in the presence 
of a normal, preserved, LVEF (Lindenfeld et al., 2010). This is most commonly 
associated with a non-dilated left ventricle. Where HFrEF is associated with systolic 
dysfunction, HFpEF is associated with incomplete or abnormal relaxation during diastole, 
and has been referred to as diastolic HF in the past. It has been suggested that HFrEF and 
HFpEF should not be considered separate conditions, but in fact they do not share same 
pathophysiology (Borlaug & Redfield, 2011; Dickstein et al., 2008). Therefore making 
the distinction may help direct more appropriate treatment as the majority of the patients 
enrolled in investigations of HF have been those with a HFrEF of <35-40% (Dickstein et 
al., 2008). Furthermore, treatments that have shown to be beneficial in HFrEF have not 
had the same efficacy when studied in patients with HFpEF (Borlaug & Redfield, 2011). 
Since, HF is a syndrome that has evolved from another cardiovascular problem, it 
should never be a patient’s only diagnosis and the underlying cause should be sought 
(Dickstein et al., 2008). Frequently, HF is described as resulting from an ischemic 
etiology, (ischemic cardiomyopathy, or ICM) or a NICM. Ischemic cardiomyopathies are 
a result of damage to the myocardium (heart muscle) related to a myocardial infarction, 
and are associated with the development of HFrEF. Non-Ischemic cardiomyopathy, 
which may lead to HFrEF or HFpEF, may be genetic (i.e. neuromuscular disorders, 
familial, inborn errors of metabolism, etc.), lifestyle-related (i.e. hypertension, obesity, 
hygiene, etc.), or idiopathic (Towbin et al., 2006). From a clinical perspective, 
distinguishing the etiology of a patient’s HF is helpful in determining the course of 
treatment to prevent further complications by the underlying disease. From a research and 
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primary prevention perspective, this distinction may also help determine the course and 
natural history of the disease that lead to the development of HF, which may be helpful in 
developing strategies to prevent the development of cardiomyopathy and HF.   
Risk Factors and Prevention of Heart Failure: 
Many risk factors that are related to coronary artery disease (CAD) are also risk 
factors for the development of either form of HF.  In the United States, it has been 
estimated that more than 60% of the cases of HF in the adult population may be 
attributable to CAD (He et al., 2001). So, include such risk factors as age, male sex, 
hypertension, left ventricular hypertrophy, obesity, diabetes, smoking, dyslipidemia, poor 
diet, sedentary lifestyle and psychological stress (Bui et al., 2011). Additionally, having a 
myocardial infarction, valvular heart disease, and alcohol abuse are considered risk 
factors for developing HF. In fact, preventable causes of HF (i.e., hypertension, obesity, 
smoking, drug or alcohol abuse) before a person is 35 years of age are important 
antecedents that may be targets for the prevention of HF (Bibbins-Domingo et al., 2009).  
Medical and Cardiac Rhythm Management of Heart Failure: 
Medical Management: Heart failure is a progressive disease and current practices 
to treat it are designed to reduce patient symptoms and to slow the progression of disease. 
These treatments include standard medical treatment with angiotensin converting enzyme 
inhibitors (ACEI), beta-blockers and diuretics, as well as cardiac rhythm management 
with electronic pacemakers and implantable cardioverter defibrillator (ICD). Subsequent 
to these primary treatments, additional medications are frequently used to treat some of 
the complications related to the development of HF. Advanced therapies, such as heart 
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transplant or implantation of a ventricular assist device (VAD) are used in the treatment 
of end-stage HF. Heart transplant has been the best treatment option for patients with 
end-stage HF for a long time, but technological advancements in VADs and increasing 
experience with utilizing VAD systems are beginning to improve 1-year survival to levels 
similar to heart transplant (Organ Procurement and Transplantation Network & Scientific 
Registry of Transplant Recipients, 2012).  
In the pathophysiology of HF, there is an association with reduced myocyte 
function with alterations such as, reduced Ca2+ sequestration by the sarcoplasmic 
reticulum (due to reduced function and expression of the sarcoplasmic reticulum Ca2+ 
ATPase) and up-regulation of sarcolemmal Na+/Ca2+ exchanger (both in function and 
expression), a reduced affinity of troponin to Ca2+, altered substrate metabolism and 
impaired respiratory chain activity (Just, 1996; Mohrman & Heller, 2010).  These 
collectively can lead to a decrease in the contractility of the heart and subsequently 
results in reduced stroke volume (reducing cardiac output), reduced arterial pressure and 
increased heart rate. Paradoxically, these alterations create changes in the force/frequency 
relationship such that contractile performance decreases with increasing heart rates; 
opposite of the normal (Bowditch-Treppe) phenomenon (Just, 1996). The decrease in 
mean arterial pressure leads to decreased arterial baroreceptor activation; impairing the 
regulation of the heart rate by the vagus nerve, but the receptors maintain the ability to 
modulate sympathetic discharge (Floras, 2009). This control of the sympathetic discharge 
increases central [medullary cardiovascular centers (Mohrman & Heller, 2010)] 
sympathetic outflow causing a further down-regulation of parasympathetic nervous 
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system (Floras, 2009). The reduced mean arterial pressure and increased sympathetic 
stimulation promote the release of renin from the kidneys (Floras, 2009), which converts 
angiotensinogen to angiotensin I, which then can be converted into the vasoconstrictor 
angiotensin II (enzymatically controlled by ACE). Angiotensin II also stimulates the 
release of aldosterone from the adrenal cortex. The decreased activation of the 
baroreceptors stimulates the release of vasopressin from the posterior pituitary, which 
(together with aldosterone) causes sodium retention and fluid absorption. Sympathetic 
stimulation of the adrenal medulla increases the release of epinephrine that further 
contributes to vasoconstriction (Mohrman & Heller, 2010). The increased circulating 
epinephrine increases glycogenolysis by the liver, which increases blood glucose levels 
and raises extracellular osmolarity. This change in osmolarity and the reduced capillary 
hydrostatic pressure from the increase arterial constriction causes a shift of fluid from the 
interstitial and intracellular spaces into the intravascular space. The intention of these 
changes, in response to the loss of cardiac output from the reduced myocyte function, is 
compensatory responses that are similarly seen in acute cardiogenic shock. This 
constellation of responses in the setting of impaired of systolic function reflects a net 
balance between appropriate reflex compensatory responses to the reduced left 
ventricular function and the stimulus eliciting the adrenergic responses excessive to what 
is needed to achieve homeostasis (Floras, 2009). When a relatively normal stoke volume 
and mean arterial pressure can be maintained through increases in left ventricular 
diastolic volume, then the balance remains shifted toward appropriate compensatory 
reflexes and plasma norepinephrine levels can be maintained (Floras, 2009). However, 
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over time, the continued increased volume contributes to cardiac remodeling and further 
myocyte dysfunction. Furthermore, the chronic norepinephrine release causes a down-
regulation in cardiac beta-1 adrenergic receptors, altered beta-receptor signal transduction 
and a decrease in norepinephrine re-uptake, tilting the balance towards the excessive 
adrenergic response (Floras, 2009). In other words, in the case of chronic HF, these 
changes can provide compensation early in the disease, but become pathologic, 
contributing to the progressive nature of HF.  
The clinical guidelines for the treatment and management of patients with HF 
published by the Heart Failure Society of America, the primary medical management of 
HF is targeted to the management of the over-activated renin-angiotensin-aldosterone 
axis and the sympathetic adrenergic system along with resulting volume overload 
(Lindenfeld et al., 2010). The primary medication used to treat the up-regulated renin-
angiotensin-aldosterone axis is ACEI. The Heart Failure Society of America recommends 
that all patients with HFrEF, whether symptoms are present or not, should be prescribed 
an ACEI (Lindenfeld et al., 2010). These medications block the conversion of the 
angiotensin I to angiotensin II by inhibiting ACE. This inhibition reduces the amount of 
angiotensin II in circulation, limiting its vasoconstrictive effects (reducing blood 
pressure) and its stimulation of aldosterone release (reducing fluid-retention). 
Angiotensin II also stimulates thirst centers in the brain, which can exacerbate the fluid-
retention in patients with HF. Therefore, limiting the amount of circulating angiotensin II 
reduces the thirst response. Unfortunately, ACE is an important enzyme in the 
degradation of bradykinin, and inhibiting it allows levels of bradykinin to build up and 
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cause a cough and angioedema. In patients that cannot tolerate ACEI due to these side-
effects, the Heart Failure Society of America recommends the use of angiotensin receptor 
blockers (ARB) in place of the ACEI (Lindenfeld et al., 2010). Where ACEI inhibit the 
conversion of angiotensin I to II, ARB block the angiotensin II type I receptors. Since 
both ACEI and ARB can similarly affect renal function and increase potassium levels, the 
Heart Failure Society of America recommends the consideration of hydralazine and oral 
nitrates in patients who are intolerant of ACEI/ARB due to renal insufficiency or 
hyperkalemia (Lindenfeld et al., 2010).  
Beta-blocker therapy for HF was once considered a contraindication as it was 
thought this would have a potential to worsen the condition. This concern was based on 
the fact that beta-blockers decrease the resting and exercise heart rate through the 
blocking of beta-adrenergic receptors, combined with the decreased LVEF in patients 
with HFrEF, would further decrease the already compromised cardiac output (Ormiston 
& Salpeter, 2003). However, as previously mentioned, the patient with HFrEF works in 
opposition to this phenomenon, and actually improves contractility with a lower heart 
rate. This has been shown in muscle preparations obtained from normal (donors that 
could not be used for transplant) hearts and from failing hearts (at the time of 
transplantation), which showed that the failing heart reached maximum tension at 
stimulation frequencies between 30-40 bpm and normal hearts reached maximum tension 
at about 170-180 bpm (Just, 1996). When studies are performed on patients with artificial 
pacemakers in the catheterization laboratory, patients without HF demonstrate no change 
in LVEF with increasing heart rates from ~80 bpm to 140 bpm; whereas patients with 
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HFrEF have dramatic decreases in the LVEF over the same HR range (Just, 1996). 
Within the same study, patients’ contractility was measured as the maximal rate of 
pressure rise (+dP/dt) over the same heart rate range, which demonstrated a dramatic 
increase in +dP/dt in patients without HF with no change in +dP/dt in patients with 
HFrEF (Just, 1996). However, studies of beta-blocker therapy with patients with HFrEF 
have shown an increase in resting LVEF after as little as three to four months of beta-
blocker therapy compared to placebo controls, with about a 29% increase in the relative 
LVEF (Lechat et al., 1998). By reducing both the left-ventricular end-diastolic volume 
and the left-ventricular end-systolic volume with an increase in LVEF, which has been 
demonstrated after four weeks of administration of carvedilol treatment compared to 
control groups, suggests that beta-blockers may cause a reverse remodeling of the heart 
(Doughty, Whalley, Gamble, MacMahon, & Sharpe, 1997). Another mechanism where 
beta-blockers appear to have an effect is an increase in the fibrillation threshold by 
slowing the heart rate and allowing more Ca2+ to be taken back into the sarcoplasmic 
reticulum by the SERCA pumps and less being removed by the Na+/Ca2+ exchangers, 
which leads to a reduction in the intracellular [Na+] reducing the development of after-
depolarization and triggered activity (Just, 1996). Beta-blockers also have beneficial 
effects on the renin-angiotensin-aldosterone axis. Blocking of renal beta1-adrenergic 
receptors decreases renin secretion. This, in turn, helps reduce blood volume and 
pressure, which reduces the amount of work (reduced O2 demand) of the heart. Through 
these various mechanisms of reducing the sympathetic over-activation, beta-blockers may 
contribute to a normalization of down-regulated receptors (or at least slow the 
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progression of down-regulation of receptors), improve contractile performance and 
provide cardio-protection (Just, 1996).  
This conclusion is evidenced in the large multi-center trials that were performed 
in the mid- to late 1990’s, which demonstrated ~5% reduction in 1-year mortality and 
reduced the number of hospitalizations in patients prescribed beta-blockers versus those 
on placebo (Pritchett & Redfield, 2002). The Metoprolol CR/XR (CR: continuous 
release; XR: extended release) Randomized Intervention Trial in Congestive Heart 
Failure (MERIT-HF) study demonstrated that metoprolol XR provided ~40% reduced 
risk of sudden cardiac death, ~34% reduced risk of overall HF-associated mortality and 
hospitalizations, and improvements in New York Heart Association HF functional class 
and perceived quality of life (Hjalmarson & Fagerberg, 2000). Similar to MERIT-HF, the 
Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial found a 
risk-reduction of ~31% in HF-related mortality and hospitalizations (Packer et al., 2002). 
The COPERNICUS trial also demonstrated fewer adverse events, such as worsening HF, 
sudden cardiac death, ventricular tachycardia and cardiogenic shock (Packer et al., 2002).  
Diuretics have a proven efficacy in patients with continued signs and symptoms 
of volume overload (i.e., orthopnea, abrupt weight gain, shortness of breath) and 
increased filling pressure (i.e., jugular vein distention, peripheral edema, pulsatile 
hepatomegaly), with loop diuretics (over thiazide-type diuretics) being the most effective 
in restoring normal status (Lindenfeld et al., 2010). The common side-effect of loop 
diuretics is hypokalemia. This is because loop diuretics increase the amount of Na+ and 
Cl- being excreted in the thick ascending segment of the loop of Henley, causing the 
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membrane potential of the lumen to increase towards the Nernst potential of K+, which 
limits the normal re-absorption/recycling of K+ (Greger, 1997). Due to this, K+ 
supplementation is frequently prescribed alongside a loop diuretic (furosemide is the 
most commonly prescribed of these medications).  
Additional medications that can be used in the care and treatment of HF include: 
aldosterone antagonists, digoxin, and a combination of oral nitrates and hydralazine 
(Lindenfeld et al., 2010).  Aldosterone antagonists further control the renin-angiotensin-
aldosterone axis by inhibiting the release of aldosterone by the adrenal medulla. These 
are recommended for patients with severe HF signs and symptoms, LVEF <35%, in 
addition to standard medical therapy – including diuretics (Lindenfeld et al., 2010). 
Digoxin is most commonly used for inotropic support in patients with LVEF <40% who 
are concomitantly taking beta-blockers and ACEI who remain symptomatic, but can also 
be used control ventricular rate when atrial fibrillation is present (Lindenfeld et al., 2010).  
Particularly for African-American patients with HF, the combination of long acting oral 
nitrates (particularly isosorbide dinitrate) and hydralazine should be considered standard 
therapy in addition to ACEI and beta-blockers (Lindenfeld et al., 2010). The results of the 
African-American Heart Failure Trial (A-HeFT), demonstrated significantly lower 
mortality rates, reduced HF-related hospitalizations and improvements in self-reported 
quality of life when this drug combination was added to standard therapy compared to a 
placebo (added to standard therapy) control group (Taylor et al., 2004). In fact, the results 
of the A-HeFT study were so striking that the study was terminated early and patients 
enrolled in the placebo group were allowed to begin the drug combination (Taylor et al., 
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2004). Further medical management should focus on other co-morbidities such as 
dyslipidemia, diabetes, and/or concomitant pulmonary disease.  
Cardiac Rhythm Management: Devices, such as implantation of an ICD with or 
without cardiac resynchronization therapy are frequently implemented in the long-term 
management of HFrEF. Based heavily on the results of the Multicenter Automatic 
Defibrillator Implantation Trials (MADIT-I and MADIT-II), the United States Food and 
Drug Administration approved the use of ICD’s for protection against ventricular 
fibrillation/tachycardia events (Moss, 2003). Sub-analysis of the results of MADIT-II 
indicated between 30-40% of patients with HFrEF as a result of myocardial infarction 
were found to have inducible ventricular tachycardia/fibrillation during electrophysiology 
studies performed at the time of implant and about 40% of the patients receiving 
appropriate defibrillation treatment during the MADIT-II study (Moss, 2003). Though the 
MADIT-I trial was primarily done as a “proof-of-concept” in patients having suffered a 
recent myocardial infarction (no inclusion/exclusion for co-existing cardiomyopathy/HF), 
the study was stopped early by the Data Safety Monitoring Board due to the 54% reduced 
risk of death in the those receiving ICD. A sub-analysis demonstrated that those with a 
reduced LVEF <25%, widened QRS complex (>120 ms), or clinical HF received the 
most benefit (Moss, 2003). 
About a third of patients with HFrEF have a left bundle branch block (LBBB) on 
their 12-lead electrocardiogram, which is indicative of right and left ventricular 
dyssynchrony and is associated with worse clinical symptoms and left-ventricular systolic 
function (Shenkman et al., 2002). In a study of 1418 patients with HFrEF first seen in a 
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community HF clinic, about 34% were found to have LBBB on electrocardiogram (Clark, 
Goode, & Cleland, 2008). In the patients without LBBB at baseline, the average QRS 
duration increased significantly from 115 to 118 ms during 1 year follow-up with an 11% 
incidence of new LBBB (Clark et al., 2008). It is this LBBB sub-population that is the 
target for cardiac resynchronization therapy. These pacemaker devices are implanted with 
three lead-wires. One wire is implanted in the right atrium (right atrial appendage), one in 
the right ventricle (typically in the apex of the ventricle) and one (the left ventricular 
lead) is advanced through the coronary sinus in one of the venous side branches running 
along the left posterior-lateral wall of the left ventricle. These systems allow the device to 
time ventricular contraction after sensing atrial contraction, and to coordinate, or 
synchronize, the contraction of the left and right ventricles. Due to the occurrence of 
ventricular arrhythmias in patients with HFrEF, cardiac resynchronization devices 
commonly contain the ability to perform defibrillation. The Comparison of Medical 
Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial was one of the 
largest trials investigating the effects of cardiac resynchronization therapy on mortality 
and hospitalizations in patients with advanced HFrEF and LBBB. This trial found a 34% 
reduction in the risk of death or hospitalization due to HF in the group receiving devices 
with defibrillation ability compared to those on optimal medical therapy (Bristow et al., 
2004). The study grouped patients into optimal therapy, device without defibrillation or 
device with defibrillation in a 1:2:2 fashion, and found that there was a 40% risk 
reduction of the combined end-points in the group with defibrillation (compared to 
optimal medical therapy), suggesting an additional benefit when defibrillation was 
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included (Bristow et al., 2004). In the Multicenter InSync ICD Randomized Clinical 
Evaluation II (MIRACLE ICD II) trial, patients with mild symptomatic HFrEF and 
LBBB were randomized to receive a cardiac resynchronization device with either the 
ICD-only or both ICD and cardiac resynchronization therapy activated. This study was 
done to show if there would be functional improvements in a group of patients with 
mildly symptomatic HFrEF (COMPANION included only patients with advanced 
HFrEF) after cardiac resynchronization therapy (Abraham et al., 2004). After 6 months of 
therapy, there were no significant differences in functional capacity (6 minute walk test 
and peak exercise VO2) or quality of life between the two groups, but the patients 
receiving therapy demonstrated improvement of ventilatory efficiency during exercise 
and signs of positive cardiac remodeling (decreased left ventricular diastolic and systolic 
volumes and increased LVEF). In a subsequent study of patients with HFrEF and LBBB 
that included patients similar to MIRACLE ICD II trial, the MADIT-CRT (cardiac 
resynchronization therapy) trial found a 35% reduction in all-cause mortality and a 63% 
reduction in HF-related hospitalizations in patients receiving cardiac resynchronization 
therapy in addition to defibrillator (Moss et al., 2009). Furthermore, patients in the group 
receiving cardiac resynchronization therapy had a significant reduction in left ventricular 
volumes and an increase of ~12% in LVEF (Moss et al., 2009). In September 2010, the 
Food and Drug Administration released a press announcement approving the indication 
that patients with HFrEF and LBBB (QRS width >130 ms if LVEF <30% and mild 
symptoms; or >120 ms if LVEF <35% and moderate to severe symptoms) that are 
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symptomatic should receive cardiac resynchronization therapy along with an implantable 
defibrillator (Thompson, 2010).  
Advanced Therapies for the Treatment of Heart Failure:   
Often, despite these advances in medical and device treatment for the 
management of HF, the best these treatments can do is to slow the progression of the 
disease. Some of these therapies (i.e., beta-blockers and cardiac resynchronization 
therapy) can cause positive remodeling of the heart, but have not been able to cure HF. In 
turn, a large number of patients eventually require more advanced treatments, such as 
cardiac transplantation and LVAD.  
The number of patients needing a heart transplant is much larger than what is 
available from donors. For example, in 2011 about 34% of patients on or added to the 
cardiac transplant waitlist received a transplanted heart and about 8% died while waiting 
in the United States (Organ Procurement and Transplantation Network & Scientific 
Registry of Transplant Recipients, 2012). Therefore, strict qualifications have been 
developed in order for patients to qualify for cardiac transplant. These qualifications are 
based on the severity of disease (i.e., severity of functional limitation); the effect of co-
morbid disease (common co-morbidities are diabetes, pulmonary disease and kidney 
disease); tobacco, alcohol and illicit-drug use; age; and psychosocial factors. These 
criteria are designed to ensure patients receiving donor hearts have the best chance for 
survival. These criteria do seem to be working. Over the past decade, 6 month and 1 year 
occurrence of graft failure has steadily declined, as has the rate of graft failure at 3, 5 and 
10 years (Organ Procurement and Transplantation Network & Scientific Registry of 
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Transplant Recipients, 2012). The overall graft survival, at the end of 2011, of patients 
receiving transplants in 2005-2006 was 75% (Organ Procurement and Transplantation 
Network & Scientific Registry of Transplant Recipients, 2012).   
Traditionally, LVADs have been used as a bridge-to-transplant in certain patients 
waiting for a donor heart to become available. However, developments in LVAD 
technology are leading to wider use of these devices and are beginning to change the face 
of advanced HF therapies. Cardiac transplantation still remains the best option for select 
patients with end-stage HF (Organ Procurement and Transplantation Network & 
Scientific Registry of Transplant Recipients, 2012), but the newest generation of LVADs 
are more durable and are beginning to be more widely used as destination therapy 
(providing an option for patients who do not qualify for transplant or who choose to defer 
it).  
The criteria for LVAD implant should begin with an assessment of functional 
capacity and should be significantly reduced similar to the peak exercise VO2 used for 
transplantation criteria (Slaughter et al., 2010). However, patients with findings of 
pulmonary hypertension during right heart catheterization who fail acute reversal 
attempts (irreversible pulmonary hypertension is an exclusion criteria for transplant) 
during the catheterization, an LVAD can be implanted to determine if mechanical support 
can reverse the pulmonary hypertension (Mehra et al., 2006), an instance of bridge-to-
decision. However, with otherwise no other options, if mechanical support cannot reverse 
the pulmonary hypertension, the LVAD would seem to be a viable alternative. However, 
when considering LVAD for destination therapy (otherwise does not qualify for 
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transplantation or if the patient defers cardiac transplantation listing), the device should 
be implanted before irreversible end-stage organ disease has been reached (Slaughter et 
al., 2010). Furthermore, patients found to be in cardiogenic shock have very poor post-
surgical outcomes with LVAD, so this should be managed prior to implantation 
(Slaughter et al., 2010). Since the LVAD assists the left heart and systemic circulation, it 
is important to determine right heart function with a right heart catheterization procedure. 
During this procedure, the right ventricular stroke work index (an indicator of the right 
ventricle’s ability to generate pressure and flow; see Table 1 for formula) can be 
calculated from the pulmonary artery pressure, central venous pressure, stroke volume 
and the patient’s estimated BSA (Slaughter et al., 2010). Patients with a right ventricular 
stroke work index of <300 mmHg x ml/m2 are considered to have poor right ventricular 
function and are contraindicated for LVAD implantation for destination therapy 
(Slaughter et al., 2010). Other requirements to ensure adequate right ventricle function 
include pulmonary vascular resistance <4 Wood units, absence of severe tricuspid valve 
regurgitation, transpulmonary gradient <15 mm Hg, right ventricular end diastolic 
volume <200 ml, and right ventricular end systolic volume of <177 ml (Slaughter et al., 
2010). All of these measures can be determined during right heart catheterization. So, 
whether the patient is undergoing work-up for cardiac transplantation or LVAD for 
destination therapy, undergoing a right heart catheterization is important for the proper 
care and treatment of the patient with HF. 
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Right Heart Catheterization 
Right heart catheterization was once performed on every patient presenting to a 
cardiac catheterization laboratory (Baim & Grossman, 2006). This procedure is the only 
way to obtain the pulmonary capillary wedge pressure (PCWP, a measure of mean left 
heart filling pressure), detect pulmonary hypertension and detect left-to-right intra-
cardiac shunts. Additionally, measurement of cardiac output by thermal dilution is 
routinely done during the right heart catheterization procedure. Due to the little added 
information from the right heart catheterization, the routine use of this procedure is 
discouraged in patients with a primary diagnosis of CAD (Baim & Grossman, 2006; 
Bashore et al., 2001). However, in patients with HF, other evidence of depressed left 
ventricular function or valvular disease, the quantification of hemodynamic function 
justifies the performance of the right heart catheterization (Baim & Grossman, 2006). In 
the case of patients with HF the quantifying hemodynamic function is useful in guiding 
therapy with diuretics, vasodilator and inotropic support (Slaughter et al., 2010) and is 
indicated for all patients being considered for LVAD and/or cardiac transplantation 
listing (Mehra et al., 2006). 
In order to perform this procedure, a femoral vein puncture is administered. 
However, the internal jugular vein may also be used, particularly when exercise 
hemodynamics are being measured. For this discussion, femoral vein access will be 
discussed, unless otherwise noted, as described in the 7th edition of Grossman’s 
Catheterization, Angiography and Intervention (Baim & Grossman, 2006). Once entry to 
the venous lumen has been accomplished, the puncture needle is removed and a sheath is 
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threaded over a guide-wire into the lumen. After removing the guide-wire, the sheath is 
flushed with a heparinized saline solution and secured in place. It is through this sheath 
that a thermistor-equipped, balloon-tip, double-lumen catheter is advanced towards the 
heart through the inferior vena cava and into the right atrium (RA). From this point, the 
catheter can be advanced or withdrawn through the right cardiac anatomy and the 
pulmonary arteries in order to obtain the various measurements necessary. Common 
measurements obtained during a right heart catheterization include; determination of left-
to-right shunt, RA pressure, right ventricular (RV) end-diastolic pressure, PWCP, 
pulmonary artery (PA) pressure and cardiac output. 
The right heart catheter allows for blood sampling at the point where the distal tip 
of the catheter is placed. Therefore, the evaluation of left-to-right shunt can be evaluated 
by simply drawing a blood sample when the catheter tip is in the superior vena cava, and 
after flushing the catheter, advancing the catheter into the PA and drawing a blood 
sample. Comparing the O2 saturation from these two locations identifies the shunt. That 
is, the O2 saturation of blood coming back to the heart from the systemic circulation 
should not change until it enters the pulmonary capillary bed where gas exchange occurs. 
Therefore, if the PA saturation is higher than what is measured from the superior vena 
cava, then oxygenated blood from the left side of the heart must be traveling through a 
shunt into the right side of the heart, increasing PA saturation. The presence of a left-to-
right shunt suggests the presence of an atrial or ventricular septal defect. 
When the catheter is advanced into the RA, systolic and diastolic pressure 
measurements can be performed and the mean RA pressure can be derived. The mean RA 
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pressure is used in the calculation of systemic vascular resistance by equation 1 in Table 
1. Systemic vascular resistance is expressed in arbitrary resistance units of mm Hg/L/min. 
These units are also referred to as hybrid resistance units or Wood units. Though these 
units are still frequently used to report findings in the United States, in Europe and in 
growing numbers in the United States, these numbers are presented in the metric units of 
dynes-sec/cm5. Wood units can be converted to dynes-sec/cm5 by multiplying the Wood 
units by 80. Normal mean RA pressure ranges from about 2-6 mm Hg, where normal 
systemic vascular resistance ranges from 11-18 Wood units (900-1440 dynes-sec/cm5). 
High systemic vascular resistance occurs with hypotension and reduced cardiac output, 
which trigger baroreceptor responses, alpha-adrenergic pathways and release of 
vasoconstrictor hormones. Low vascular resistance is seen in high output states 
(high blood flow), such as severe anemia or arteriovenous fistula. 
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Table 1. Select Variables Derived during Right Heart Catheterization 
and the Formulas to Derive the Variable. 
 
 Variable Formula Units 
Right Ventricular Stoke Work 
Index ((mPA - mCVP)*SV)/BSA mmHg*ml/m
2 
Systemic Vascular Resistance (mAo - mRA)/C.O. Wood Units 
Valvular Orifice Area (Gorlin 
Formula) 
(C.O./([DFP or 
SEP]*HR))/44.3C*√ΔP) cm
2 
Mitral Valve Orifice Area (C.O./(HR*DFP))/(44.3*0.85*√ΔP) cm2 
Total Pulmonary Resistance mPA/pulmonary C.O. Wood Units 
Pulmonary Vascular Resistance (mPA - mLA)/Pulmonary C.O. Wood Units 
mPA = mean pulmonary artery pressure; mCVP = mean central venous pressure; BSA = 
body surface area; mAo = mean aortic pressure; mRA = mean right atrial pressure; C.O. 
= cardiac output; DFP = diastolic filling pressure; SEP = systolic ejection pressure; HR 
= heart rate;   C = constant; ΔP = mean pressure gradient across the valve; mLA = mean 
left atrial pressure. 
 
 
When the catheter tip is advanced from the RA, through the tricuspid valve and 
into the RV, systolic and diastolic RV pressure can be measured. Measured at the end of 
diastole, the diastolic pressure has shown to provide indication of impending HF 
decompensation and poor prognosis (Voelkel et al., 2006). Therefore, it is common 
practice to only measure the end-diastolic RV pressure. Normal ranges of end-diastolic 
RV pressure range from 0-8 mm Hg. It has been shown that there is an inverse 
correlation between end-diastolic RV pressure and RVEF (Bleasdale & Frenneaux, 
2002). Measurements of RVEF in patients with HF have been shown to be prognostic 
independent of the LVEF (Bleasdale & Frenneaux, 2002; de Groote et al., 1998). 
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Advancing the catheter from the RV through the pulmonic valve, the catheter can 
be advanced into a small pulmonary arterial branch where it can be wedged. According to 
Baim, the appropriate “wedge” positioning can be confirmed when the catheter can no 
longer be advanced; even after having the patient cough (Baim & Grossman, 2006). 
Additionally, visual inspection of the resulting waveform (compared to a standard 
waveform) and/or >95% O2 saturation of sampled blood through the catheter can confirm 
a true wedge position (Baim & Grossman, 2006). A normal PCWP can range from 6-12 
mm Hg. In patients with HF, a PCWP <16 mm Hg has been associated with improved 
outcomes. An appropriately confirmed PCWP has been shown to be a reliable measure of 
left atrial pressure. This is due to the continuity of the pulmonary circulatory system 
transmitting the left atrial pressure signal back through pulmonary veins and capillaries 
(Baim & Grossman, 2006). That is, when the catheter is wedged, the pulmonary 
vasculature forward of the catheter tip acts like an extension of the catheter, providing 
useful information about the left atrial pressure. This can provide information regarding 
changes in left atrial compliance. Furthermore, this relationship is helpful in avoiding the 
direct measure of left atrial pressure, which requires a trans-septal approach that is 
associated with serious complications. It is necessary to have the left atrial pressure in 
order to quantify the trans-mitral pressure gradient and mitral valve area (Lange, Moore, 
Cigarroa, & Hillis, 1989). However, this has come into question in patients with existing 
mitral valve stenosis, as it consistently overestimates the transmitral pressure gradient 
and, therefore, the severity of the mitral stenosis in these patients (Hildick-Smith, Walsh, 
& Shapiro, 2000; Nishimura, Rihal, Tajik, & Holmes, 1994). Despite this, when the 
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appropriate wedge position is confirmed with the oximetry method stated previously 
(Alpert, 1989), a relatively small error in left atrial pressure is seen (Lange et al., 1989). 
The formula for calculating any valve orifice area (Gorlin Formula) is used for the 
measurement of mitral valve orifice area (Table 1), whereas the specific equation for the 
measurement of the mitral valve orifice area is exampled in Table 1. In the equation 
presented in Table 1 the empirical constant (C) 0.85 accounts for the coefficient of 
velocity and the coefficient of orifice contraction.  
Once the PCWP is obtained, the catheter is often withdrawn into a more proximal 
(to the heart) left or right PA. At this point the PA pressures can be recorded. The PA 
diastolic pressure is a reliable indicator of a patient’s volume status. This value is 
particularly important in the determination of total pulmonary resistance and pulmonary 
vascular resistance (Table 1). 
As can be seen in the preceding four equations (summarized in Table 1), the 
cardiac output is used in all these. This makes the accurate and reliable measure of 
cardiac output key to quantifying the full cardiac hemodynamic function in those patients 
undergoing right heart catheterization. Currently, there are two methods in determining 
cardiac output utilized in the catheterization laboratory.  
One method of measuring cardiac output (indicator dilution method) is performed 
while the catheter tip is in the PA (typically at the same location where PA pressure is 
measured) and involves the injection of a nontoxic injectant the concentration of which 
can be accurately measured. Dye dilution methods are used, but cool-fluid (thermal 
dilution) methods are most common. Regardless of the method, the dilution of the 
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indicator (dye concentration or temperature change) is used to determine the cardiac 
output based on the Henderson-Hasselbach equation, which can be seen in Table 2 (Baim 
& Grossman, 2006). The second method of measuring cardiac output is based on the Fick 
equation (Table 2), which involves the measurement or estimation of resting VO2 and the 
measurement of the a-vO2diff. Each of these two techniques will be discussed in detail in 
following sections. However, it may be beneficial at this point to discuss cardiac output
in greater detail. 
 
 
Table 2. Formulas for Calculating Cardiac Output with Thermal Dilution and Fick 
Methods. 
 
Method Formula 
Henderson-Hasselbach Equation VI(TB - TI)(SI*CI/SB*CB)60(sec/min)/ ΔTB(t)dt 
Fick Equation VO2/((Ao sat - SVC sat)*(Hgb*(1.36)*(10))) 
VI = volume of injectant; TB or I = temperature of blood or injectant; SB or I = specific 
gravity of blood or injectant; CB or I = specific heat of blood or injectant; ΔTB(t)dt = 
change in temperature of the blood downstream from the injection site; Ao sat = aortic 
oxygen saturation; VO2 = oxygen consumption; SVC sat = superior vena cava oxygen 
saturation; Hgb = hemaglobin concentration.    
 
 
Cardiac Output 
As illustrated in Table 1 there are several hemodynamic measurements that can 
be made or estimated during a right heart catheterization. Among these is the estimation 
of cardiac output. Cardiac output is typically defined as the quantity, or volume, of blood 
delivered to the systemic circulation per unit of time, and is normally expressed in liters 
per minute (L/min). In other words, this is the volume of blood that is flowing through 
the body per minute, which is responsible for the transporting of substances to and from 
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the body’s tissues. Corresponding with cardiac output is venous return, which is the 
volume of blood that is flowing back into the heart (right atrium) from the peripheral 
circulation. When cardiac output is unchanging, venous return is equal to cardiac output. 
However, when cardiac output is changing, these two values will vary temporarily (for at 
least a few heartbeats) as blood is being stored or removed from capacitance vessels (i.e. 
medium to large veins), the lungs and the heart. It is generally accepted that a typical, 
resting cardiac output is about 5 L/min and can increase to levels >35 L/min during heavy 
exercise in elite endurance athlete. In a classic study, Brandfonbrener and colleagues 
found a mean cardiac output of 5.08 + 1.51 L/min in 60 patients between the age of 19-86 
years-old (mean 52.5 years) who were absent of cardiac disease using a dye dilution 
method (Brandfonbrener et al., 1955). It was further found that cardiac output decreases 
with age ~1% per year between 20 and 89 years of age (Brandfonbrener et al., 1955).  
When considering cardiac output as a clinical variable, it is often better to index it 
to BSA. Dividing cardiac output by BSA (cardiac index) provides a better indicator of the 
heart’s performance as a pump to circulate O2 and nutrients to the body’s tissues. For 
example, a person with a cardiac output of 5 L/min and a BSA of 1.79 m2 would have a 
cardiac index of 2.8 L/min/m2. However, a person with the same cardiac output and a 
BSA of 2.22 m2 would have a cardiac index of 2.2 L/min/m2. Thus, it may be a more 
sensitive indicator of cardiac function than the absolute cardiac output. The normal range 
of cardiac index is about 2.6-4.2 L/min/m2, with a mean of ~3.0 L/min/m2 in normal 
health adult subjects, with no significant difference between males and females 
(Brandfonbrener et al., 1955). Similar to what was found with cardiac output, the cardiac 
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index decreases with age of ~1% per year in adults (Brandfonbrener et al., 1955). A 
cardiac index of <2.6 L/min/m2 is considered abnormal and is consistently found in 
patients with HF (Carlsson et al., 2012; Cotter et al., 2003). Clinically significant hypo-
perfusion is considered when the cardiac index becomes <2.2 L/min/m2 and cardiogenic 
shock is considered when the cardiac index falls below 1.9 L/min/m2 (Ginsberg & 
Parrillo, 2009). Cardiogenic shock is associated with early death (within 3 months) after 
implant of LVAD (Kirklin et al., 2010), and is therefore important to take steps to 
improve this situation and attempt to improve cardiac index towards 2.2 L/min/m2 
(Slaughter et al., 2010). 
Though the measurement of the cardiac output and deriving the cardiac index are 
clinically important, the measurement of cardiac output is an important variable in the 
calculation of a number of derived variables (as described above in the description of the 
right heart catheterization procedure and summarized in Table 1). In the use of right 
heart catheterization in the decision for candidacy for heart transplantation, the 
measurement of the pulmonary vascular resistance (absolute or indexed to BSA) is 
important in risk stratification for successful post-transplant outcomes (Mehra et al., 
2006).  
Thermal Dilution Cardiac Output 
One of the methods used to obtain cardiac output is an indicator dilution 
technique. The most common of these techniques is the thermal dilution technique, 
although dye-dilution techniques using indocyanine-green dye have been used (these 
have fallen out of favor due to difficulty with obtaining the dye). The thermal dilution 
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technique uses a cold fluid as the indicator, which is then diluted (warmed) by the 
circulating blood. There are two techniques used during any indicator dilution methods: 
continuous-infusion and single-injection techniques. The single injection technique is the 
most widely used and is the technique used in catheterization laboratories (Baim & 
Grossman, 2006). Therefore, the single injection technique of the thermal dilution 
method will be discussed. All indicator dilution techniques capitalize on the Law of the 
Conservation of Mass-Energy, which states that mass, or energy, cannot be created or 
destroyed. That is, they are simply applications of the general Fick principle. In fact, in 
the VO2 method, the indicator is the O2 that is inspired into the lungs continuously. There 
are four fundamental requirements for the single injection method (Baim & Grossman, 
2006). 
The first requirement states that the nontoxic injectant should mix completely 
with the blood and its concentration should be able to be accurately measured (Baim & 
Grossman, 2006). In the thermal dilution method, the injectant is either a saline solution 
(5% dextrose mixed in water can also be used) which is either cooled to a pre-determined 
temperature (most common) or is at room temperature. It is important to point out that 
temperature is the indicator in this method, and in order to measure its “dilution” one 
needs to know the starting temperature. Originally, the thermal dilution method was done 
with a dual-thermistor set-up. However, most commercial systems utilize a single 
thermistor catheter, but dual thermistor systems have been re-visited and have 
demonstrated superiority over single thermistor systems (Lehmann & Platt, 1999). 
Despite this evidence, single thermistor systems still persist and remain the most common 
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set-up. The single thermistor system requires measurement of the temperature of the 
injectant prior to injection and that temperature needs to be corrected by a known 
constant to account for catheter warming. However, the value of this constant has come 
in to question, particularly because it does not account for the variation in warming due to 
the operator’s hands (Lehmann & Platt, 1999). In an important study by Lehmann and 
Platt, they measured single and dual thermistor cardiac outputs in 50 non-emergent 
patients (totaling 960 cardiac outputs) with and without definite indications for right heart 
catheterization (Lehmann & Platt, 1999). They found wide variation in the resulting 
cardiac output with single thermistor technique compared to Fick VO2 (Fick) cardiac 
output (mean error of about 25%) versus the dual thermistor cardiac output compared to 
the Fick cardiac output (mean error of about 17%). Although single thermistor techniques 
are still used, dual thermistor techniques appear to provide a more accurate measurement 
of the injectant temperature at the injection site, and therefore more accurate 
measurement of the dilution. 
The second requirement for the single-injection method is that the indicator 
substance is not added to or subtracted from the blood between the injection site and the 
sampling site. In the thermal dilution method, the change in temperature is related to the 
injectant being diluted by the warmer blood. Therefore, the thermal dilution method 
meets this requirement in most patients. However, this may not be true in patients with 
low output states (van Grondelle et al., 1983). In a set of 16 patients with Fick cardiac 
outputs <3.5 L/min (van Grondelle et al., 1983), the thermal dilution method 
overestimated cardiac output compared to the Fick cardiac output in all the patients, 
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reaching an overestimation of cardiac output of >35% in patients with cardiac output 
<2.5 L/min. These results suggest a systematic error in the measurement in these patients, 
which means that either the Fick method underestimates true cardiac output or the 
thermal dilution overestimates it in this patient group. However, as mentioned above, in 
such low output states, the a-vO2diff is increased. This makes the relative errors in its 
measurement small, and in turn, provides the Fick cardiac output greater accuracy (van 
Grondelle et al., 1983). It is postulated in such low flow, low output states that there is 
loss of indicator (temperature) that is related the warming of the blood by the walls of the 
heart chambers and surrounding tissue (Baim & Grossman, 2006; van Grondelle et al., 
1983). That is, the integrated signal that is sampled demonstrates a greater temperature 
increase due to the greater time the indicator is exposed to the cardiac tissues (van 
Grondelle et al., 1983). This theory is supported by the evidence of prolonged circulation 
time in patients with HF (Morris et al., 2007). In a study of 30 patients with chronic 
systolic HF, resting lung-to-lung circulation time was measured by determining the time 
taken for a bolus of inhaled acetylene to travel from the lungs, through the systemic 
circulation and back to the lungs (Morris et al., 2007). The results of this study 
demonstrated that the severity of HF increased with increased lung-to-lung circulation 
time (Morris et al., 2007). 
The third requirement is that the majority of the indicator must pass the sampling 
site before it is re-circulated (Baim & Grossman, 2006). When the indicator is injected 
into the RA (or less commonly the vena cava) the blood flow must travel forward into the 
RV and into the PA. Therefore, it is logical that regurgitant flow through the tricuspid 
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valve will cause the indicator to be re-circulated back into the RA before it can be 
sampled. Similar to situations of low output, the indicator is exposed to the blood and 
cardiac tissues for a longer period of time. This will cause an increase in the temperature 
at the sampling site and then overestimate cardiac output. Tricuspid regurgitation occurs 
in about 15% of men and 18% of women in the general population in the United States 
(Roger et al., 2012). This is a common exclusion criterion in studies measuring thermal 
dilution cardiac output (Bergstra et al., 1995; Berthelsen, Eldrup, Nilsson, & Rasmussen, 
2002; Dehmer et al., 1982; Lehmann & Platt, 1999). As such, it is recommended that this 
technique should not be used in patients with severe tricuspid regurgitation (Baim & 
Grossman, 2006).  
The fourth and last requirement for the single injection method states that the 
indicator must traverse some part of the central circulation where mixing of all the blood 
from the body occurs (Baim & Grossman, 2006). As stated previously, the two most 
common sites of injection are the RA and the vena cava. In patients with sinus rhythm 
and remaining in a steady resting state, demonstrate a relatively constant stroke volume 
with each cardiac cycle. Therefore, mixing of the blood is very consistent; making 
injection just outside (vena cava) or within the RA meet this criteria. However, in 
situations where variations in RV filling times and stroke volume cause the cardiac 
output to become cyclic. For example, Østergaard et al. compared 25 patients with atrial 
fibrillation and 22 patients with sinus rhythm and found that patients with atrial 
fibrillation had a 55% higher random error (less precise measure of cardiac output) 
compared to patients with sinus rhythm (Østergaard, Nilsson, Nilsson, Rasmussen, & 
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Berthelsen, 2005). Additionally, they were able to measure cardiac outputs in 8 patients 
in atrial fibrillation group after they converted to sinus rhythm, which demonstrated 
improved precision to a level more comparable to those in the sinus rhythm group 
(Østergaard et al., 2005). It was postulated in this study that their results likely show 
much greater random error because of the compounding effect of the random error 
associated with the single injection method (same for both groups) and the variable 
cardiac output that results from atrial fibrillation (Østergaard et al., 2005). However, the 
patients in atrial fibrillation in this study had controlled ventricular rates, which may have 
improved the overall precision in this group (Østergaard et al., 2005). Though atrial 
fibrillation is problematic, in situations where there is good rate control, performing more 
cardiac outputs injections and taking an average of these may provide a better idea of the 
patients overall cardiac output. It is common practice to perform three to five thermal 
dilution cardiac outputs in all patients with an average of the closest three to four 
measurements (Nilsson, Nilsson, Skovgaard, & Berthelsen, 2004). In patients with atrial 
fibrillation, it may be necessary to perform even more measurement trials. 
Fick Cardiac Output 
As mentioned above, the Fick equation for measuring cardiac output is an 
application of the Law of Mass/Energy Conservation (same as indicator dilution 
methods), where the indicator is the O2 that is inspired into the lungs continuously. That 
is, the theoretical principles proposed by Adolph Fick in 1870 are the common 
underpinning to both the thermal dilution and Fick VO2 techniques. The simplified Fick 
equation for measuring cardiac output is: Cardiac Output = VO2/a-vO2diff. 
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When determining cardiac output with the Fick Method, the measure of VO2 
through metabolic gas exchange measured at the mouth is considered the gold standard. 
In fact, prior to the introduction of the thermistor-equipped catheter in 1971, the Fick 
cardiac output was the standard method. 
Measurement of Resting Oxygen Consumption 
Measurement by Ventilatory Gas Exchange: 
Ventilatory gas analysis is the most common method used for both quantifying 
metabolic rate and energy expenditure, and metabolic carts that measure gas exchange 
from expired breath during rest and exercise are widely available from commercial 
manufacturers. In order to calculate metabolic data, all of these systems need to measure 
fractional concentrations of O2 and carbon dioxide in expired air along with minute 
ventilation. Although hardware and software specifications vary, all systems contain the 
basic components of flow/volume transducer and gas analyzers. From these, VO2, carbon 
dioxide production, and the respiratory exchange ratio can be calculated as frequently as 
breath-by-breath in many commercial systems.  
The major source of error relating to the Fick method for estimating cardiac 
output is the assessment of VO2 with an average error of the measurement of 4 - 6% 
(Armstrong & Costill, 1985; Novitsky, Segal, Chatr-Aryamontri, Guvakov, & Katch, 
1995). During the measurement of VO2 at rest, prior to catheterization, the primary 
contributors of error are sedation (Wolf et al., 1998) and the changes in breathing patterns 
related to the instrumentation (Perez & Tobin, 1985).  
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Sedation given to patients prior to catheterization can vary between patients and is 
often left to physician discretion. Any sedation will cause a decrease in metabolism, 
reflecting in a decrease in VO2 (Wolf et al., 1998). However, in the context of the right 
heart catheterization, it is important to obtain the resting VO2 under the conditions of the 
right heart catheterization.  
It is well established that changes in tidal volume and breathing frequency occur 
when a patient’s breathing is being monitored (Perez & Tobin, 1985). This appears to be 
particularly true when a patient breathes through a mouthpiece with nose clips blocking 
the nose, where increases in tidal volume can exceed 20% (with a particular increase in 
length of time for inspiration) and decreases in breathing frequency can reach 7% or more 
(Perez & Tobin, 1985). These alterations in breathing can change the work of breathing 
and influence the resting VO2. Despite these limitations, the use of the mouthpiece and 
nose clip during the measurement of VO2 is quite common and many ways is better than 
the alternative methods. For example neoprene facemasks and hoods that cover the entire 
face and head have demonstrated similar changes in breathing patterns as seen with 
mouthpiece and nose clips (Perez & Tobin, 1985). Facemasks cannot provide an 
appropriate seal in those with flattened facial features or those with facial hair around the 
mouth and chin. Hoods, however, significantly reduce the risk of air leaks, but may allow 
the mixing of “room air” with exhaled air within the hood space and are associated with 
greater anxiety due to claustrophobia (Wolf et al., 1998). When the instantaneous 
collection of breath-by-breath gas exchange is performed, the instantaneous display of 
gas exchange values for each breath can be displayed and allows the technician an 
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opportunity to recognize the air leak and correct it. Furthermore, in the post-test analysis, 
data from leaked breaths can be excluded when collected breath-by-breath reducing the 
error related to air leaks.  
Partly due to these limitations and, likely more importantly, the ease of using 
standardized equations have led researchers and clinicians to develop estimation 
equations as a surrogate to measuring the VO2 in the calculation of cardiac output by the 
Fick Equation. In the catheterization laboratory, the main purpose of the estimation 
equations were a back-up when the measurement of resting VO2 was determined to be 
inaccurate or unreliable during an individual procedure (Bergstra et al., 1995; Dehmer et 
al., 1982; LaFarge & Miettinen, 1970). However, most catheterization laboratories have 
adopted the practice of using one of three popular estimation equations (Bergstra et al., 
1995; Dehmer et al., 1982; LaFarge & Miettinen, 1970) exclusively over measuring VO2 
(Narang et al., 2012). The estimation equations capitalizing on the accepted and well 
demonstrated fact that the resting VO2 per unit body mass is greater in males than in 
females, greater in children than in the aged, greater in small individuals than in large 
ones, and higher under stress conditions (Brooks, Fahey, & Baldwin, 2005), all three of 
the widely used estimation equations include BSA in the calculation (Bergstra et al., 
1995; Dehmer et al., 1982; LaFarge & Miettinen, 1970). Two of the equations have used 
age, sex and heart rate at the time of measurement in order to improve estimated accuracy 
(Bergstra et al., 1995; Dehmer et al., 1982; LaFarge & Miettinen, 1970). The formulas for 
each of the estimations is listed in Table 3. 
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Table 3. Equations Used to Estimate Oxygen Consumption.  
Estimation Equation Formula 
LaFarge & Miettinen (1970) - 
Male (138-(11.49*ln(Age))+(0.378*HR))xBSA 
LaFarge & Miettinen (1970) - 
Female (138-(17.04*ln(Age))+(0.378*HR))*BSA 
Demer, Firth & Hillis (1982) 125*BSA 
Bergstra, van Dijk, Hillege, et 
al. (1995) 
(157.3*BSA)+(100*Sex[0 for female; 1 for male])-
(10.5*ln(Age))+4.8 
ln(Age) = natural log of age; HR = heart rate; BSA = body surface area (Du Bois and Du 
Bois (1916) formula)  
 
 
Before discussing each of these estimation equations, it is important to have a 
brief discussion of the calculation of BSA. Referring back to Table 1, the right 
ventricular stroke work index is indexed to BSA, referring back to the discussion of 
cardiac output it is often indexed to BSA in order to standardize cardiac output and 
provide information concerning the effectiveness of the measured cardiac output, and 
lastly all the estimation equations have utilized BSA in the estimation of VO2. Though 
there are several estimations of BSA from different authors, the most widely used 
(including all the authors of the VO2 estimation equations) is the equation of Du Bois and 
Du Bois (Verbraecken, Van de Heyning, De Backer, & Van Gaal, 2006). The estimation 
of BSA by Du Bois and Du Bois was based on cadaver studies of 9 European adult males 
(Du Bois & Du Bois, 1916), which would certainly seem to limit how the equation could 
be generalized across ethnicity, sex and age. Furthermore, studies performed on larger 
cohorts of individuals have determined that the formula by Du Bois and Du Bois 
consistently underestimates BSA (Haycock, Schwartz, & Wisotsky, 1978; Verbraecken et 
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al., 2006). In obese (BMI > 30 kg/m2) adults, the DuBois and DuBois formula 
underestimate BSA by 2.7% in males and 4.5% in females (Verbraecken et al., 2006). 
Considering determination of conditions like cardiogenic shock are partly determined by 
a reduced cardiac index (cardiac output/BSA), underestimating the BSA in this 
calculation would result in a higher cardiac index and result in inadequate treatment 
(Verbraecken et al., 2006). Despite these findings, the estimation by Du Bois and Du 
Bois remains widely used in the cardiac catheterization laboratory (Baim & Grossman, 
2006), and (as already stated) is employed in the most widely used VO2 estimations. The 
formula from Du Bois and Du Bois (Du Bois & Du Bois, 1916) is: 
  
BSA=0.00718 * Height (cm)0.725 *Weight (kg)0.425 
 
 
Equations Derived by LaFarge & Miettinen: 
In 1970, LaFarge & Miettinen published their findings of the indexed VO2 
(VO2/BSA) in 879 patients undergoing cardiac catheterization (LaFarge & Miettinen, 
1970). To date, this study contains the largest cohort of patients undergoing cardiac 
catheterization where VO2 was measured. Prior to this publication, other researchers had 
published results (with prediction equations and nomograms) for infants, children and 
adults in the basal condition, basal metabolic rate. LaFarge & Miettinen suggested that 
utilizing results from these previous studies to predict resting VO2 in those undergoing 
cardiac catheterization would lead to erroneous results. One of their primary arguments 
was that patients undergoing catheterization are not in the basal state, because the patient 
can be under some stress from undergoing the procedure (LaFarge & Miettinen, 1970). In 
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1970, the most widely used estimate for resting VO2 was from Rudolph and Cayler 
(Rudolph & Cayler, 1958). In this older study, the authors reported an age-specific 
estimate of basal VO2. With the estimate derived from 126 patients, one of the limitations 
to this older study is the small cohort and its exclusive assessment with pediatric 
populations (Rudolph & Cayler, 1958). Furthermore, LaFarge & Miettinen argued that 
estimating VO2 from age alone is insufficient, and that other variables such as sex, heart 
rate, a-vO2diff and arterial saturation (along with age) influence VO2 (LaFarge & 
Miettinen, 1970). 
 In their study, all patients between the ages of 3 and 40 years old undergoing 
cardiac catheterization over an almost six year period were included, which resulted in a 
total of 879 patients. Expired air was collected for all patients over a three-minute period 
into a Douglas bag by way of a two-way valve and mouthpiece/nose clip. The 
concentration of O2 in the expired air (in the Douglas bag) was measured by a pO2 
analyzer, and the volume of air was measured by evacuating the Douglas bag through a 
Collins Tissot spirometer. Room air was assumed to contain 21% O2. After obtaining the 
data, fitted regression models were run which included variables such as age, sex, heart 
rate, arterial O2 saturation, a-vO2diff and BSA. Standard error was computed for each 
model derived and the estimates were compared to zero. The best-fit equations for males 
and females can be found in Table 3. Interestingly, the measured results were never 
compared to the nomograms of Rudolph and Cayler, which were reportedly widely used 
during this time period (LaFarge & Miettinen, 1970). Another major limitation to the  
 
53 
 
study is the lack of patients over the age of 40, and with a mean age of 13 years for the 
sample implies a majority of pediatric patients.  
 Several studies have revisited the findings of the formulas developed by LaFarge 
& Miettinen. In these studies, the VO2 was either measured through metabolic gas 
exchange (Fakler et al., 2005; Kendrick et al., 1988; Narang et al., 2012; Narang et al., 
2014; Wolf et al., 1998) or calculated by back calculating the VO2 from the dye-dilution 
cardiac output (Bergstra et al., 1995; Dehmer et al., 1982). Figure 1 summarizes the 
findings of these studies with a plotting of the mean difference of the estimated VO2 by 
the formulas of LaFarge & Miettinen minus the measured VO2, with variance represented 
by the 95% confidence interval. Overall, studies with primarily adults (Fakler et al. 
enrolled primarily pediatric patients) show that in a wide variety of patients the formulas 
derived by LaFarge & Miettinen underestimate the resting VO2 (Figure 1). However, in 
all the studies reported, including the relatively small difference reported by Kendrick et 
al. (mean difference -0.44 ml/min/m2), mean differences were found to be significantly 
different than zero by t-test analysis (Bergstra et al., 1995; Fakler et al., 2005; Kendrick 
et al., 1988; Narang et al., 2012; Narang et al., 2014). Furthermore, all studies analyzed 
the agreement between the measured and estimated VO2 utilizing the methods of Bland 
& Altman (Bland & Altman, 1986), and found a systematic error in the formulas of 
LaFarge & Miettinen where lower values of VO2 were overestimated and higher values 
of VO2 were underestimated, which results in poor agreement between the two measures. 
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Importantly, the studies by Kendrick et al., Wolf et al. and Narang et al. (2014) 
utilized primarily adult patient groups representative of type of patient seen in an adult 
cardiac catheterization laboratory with measurement of resting VO2 with gas exchange 
similar to the method of LaFarge & Miettinen. In the study by Kendrick et al., 80 adult 
patients (age 59 + 8, range 38-78 years) were undergoing routine left and right heart 
catheterization as part of their assessment for various (no specific conditions mentioned) 
cardiac disorders (Kendrick et al., 1988) and it is likely that at least some of these patients 
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had reduced systolic function. None of the patients received sedation prior to 
catheterization, which is unlike the methods of LaFarge & Miettinen. The age range of 
the patients starts at the upper end of the range analyzed by LaFarge & Miettinen. One 
reason for such agreement between the measured and estimated VO2 may be related to 
the fact the expired gas exchange was collected into a Douglas bag through a two-way 
valve and mouthpiece and analyzed (room air O2 was assumed at 21%) in a similar 
fashion to the methods described by LaFarge & Miettinen (LaFarge & Miettinen, 1970). 
Where patients were sedated in the LaFarge & Miettinen study, the reduction in VO2 
caused by the use of sedation in their younger cohort may have been off-set by the older 
age of the patients studied by Kendrick et al. In fact, this would be consistent with the 
trend in the findings of LaFarge & Miettinen that demonstrated a decrease of ~0.4 
ml/min/m2 per half-decade after the age of 20. If this trend remains beyond the age of 40, 
then the results from Kendrick et al. are consistent with LaFarge & Miettinen. Likewise, 
the patients in the study by Wolf et al. were also primarily adult patients (mean age 52.2, 
range 16-68 years old) with diagnosis of cardiomyopathy (47 patients), valvular disease 
(3 patients) or post cardiac transplant (7 patients) who were scheduled to undergo 
maximal cardiopulmonary exercise testing (Wolf et al., 1998). Prior to beginning exercise 
testing, patients’ resting VO2 was measured by breath-by-breath respiratory gas exchange 
while lying in a supine position (Wolf et al., 1998). These methods utilized are quite 
different than those described by LaFarge & Miettinen, particularly in the methods used 
to analyze the metabolic gas exchange (computerized metabolic cart vs Douglas bags) 
and the fact that these patients were preparing to undergo an exercise stress test instead of 
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a cardiac catheterization. Measuring the gas exchange through breath-by-breath analysis 
of inspired and expired air is well validated and may provide some advantage of detecting 
air leaks on the mouthpiece. Measuring the resting VO2 prior to exercise testing indicates 
these patients did not receive any sedation. So, it is not surprising that the estimated VO2 
by LaFarge & Miettinen underestimated the resting VO2. Most recently, Narang et al. 
(2014) published results from a retrospective analysis of 10 years’ worth of data. Resting 
VO2 was measured by the Douglas bag method in 535 adults patients (mean age 55 + 
13.5 years) undergoing routine right heart catheterization (Narang et al., 2014). Among 
the 535 patients, 102 (19%) had a diagnosis of HF, but no sub-analysis was performed on 
this particular subgroup. Where Kendrick et al. and Wolf et al. reported their findings 
indexed to BSA, Narang et al. (2014) reported their findings in ml/min making the 
comparison difficult. When roughly indexing the mean difference in resting VO2 by an 
estimated average BSA of 1.89 m2 (from the reported average height and weight), the 
results of Narang et al. (2014) still show a greater underestimation than Wolf et al. (-17.5 
vs. -7.9, respectively). Narang et al. (2014) make no mention of sedation, which limits the 
understanding of these results. 
Prior to the results reported in 2014, Narang et al. (2012) reported results from 75 
lean and obese adults (median age of 39 years old, mean BMI 33 kg/m2) prior to exercise 
testing during their participation in two other studies. Though the measurement of gas 
exchange was done in the same manner as LaFarge & Miettinen (expired air collected 
into Douglas bags through a mouthpiece), 27 participants were standing during the 
resting data collection and the remaining 48 subjects were seated on a recumbent bike 
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(Narang et al., 2012). So, again the absence of sedation and the additional deviation of 
body position and body habitus are likely contributors as to why these findings are so 
divergent from the other studies (Figure 1). However, the results between the 2012 and 
2014 analyses appear to be what would be expected. That is, non-patient volunteers 
undergoing exercise stress testing will have a higher resting VO2 than patients 
undergoing cardiac catheterization (assuming sedation was given to the patients).      
Equation Derived by Dehmer, Firth and Hillis: 
Of the three equations presented here, the 125 x BSA equation is probably the 
most widely used. Primarily, this is related to the fact that it has been put forth as an 
acceptable estimation for resting VO2 in authoritative texts and statements of clinical 
practice (Baim & Grossman, 2006; Bashore et al., 2001; Summerhill & Baram, 2005). 
However, none of these publications offer any reference for the origins or validation of 
this equation. A recent publication references the “Parkland Equation” to a 2005 review 
paper by Summerhill and Baram (Narang et al., 2012). The review paper lists the 
equation in a table (with no reference), and suggests using it when measuring VO2 is not 
possible (Summerhill & Baram, 2005). The expert consensus statement from the 
American College of Cardiology and the Society for Cardiac Angiography and 
Interventions recommends use of either “established reference table or the following 
formula: [VO2] = 125 mL/min/m2 BSA” (Bashore et al., 2001), but again offer no 
reference to origins of this equation. During some investigation into previous editions of 
Grossman’s Cardiac Catheterization, Angiography and Intervention textbook, a reference 
to research performed by Dehmer et al. (Dehmer et al., 1982) was cited as the source of 
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this formula. This finding was confirmed with the second paper published by Narang in 
2014, where the authors no longer refer to it as the “Parkland Formula”, but the “Dehmer 
Formula” (Narang et al., 2014).  
Dehmer et al. sought to determine the variability of resting VO2 in a sample of 
164 adults between the ages of 21-75 years old (mean age of 50 years) who were referred 
for cardiac catheterization (Dehmer et al., 1982). Though patients were referred for 
cardiac catheterization for clinical indications, patients with valve regurgitation, inter-
cardiac shunting or low cardiac output (<3.5 L/min) were excluded from their analysis. 
Instead of measuring VO2 with ventilatory gas exchange, the resting VO2 in each patient 
was back calculated from the measured cardiac output and a-vO2diff through the Fick 
Equation. There were more than 50 patients that did not receive sedation and on average 
had higher resting VO2 measurements than did the remaining patients who received 
sedation. In the study by LaFarge & Miettinen, all patients received some level of 
sedation. Unfortunately, Dehmer et al. did not estimate resting VO2, and therefore there 
was no direct comparison between their measurement of VO2 and that estimated by the 
equations of LaFarge & Miettinen. Although they found an average, indexed to BSA, 
VO2 of 126 +26 ml/min/m2, which was similar to what can be derived from the data 
reported by LaFarge & Miettinen in their adult cohort (126 +15 ml/min/m2, derived from 
the data presented in LaFarge & Miettinen, 1970), they also reported a large range of 65-
250 ml/min/m2. This large range led them to conclude that with such a wide range, 
estimating the VO2 on an individual may be severely inaccurate, and the subsequent  
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computing of cardiac output would lead to significant miscalculation of valve area, 
regurgitant fraction and vascular resistance (Dehmer et al., 1982).  
This study was not performed with the intention of developing an estimation 
equation and, in fact, the study did not offer an estimation equation. The authors report 
the average indexed VO2 among the 108 patients in the study was 126 +26 ml/min/m2 
with a large range of values between 65-250 ml/min/m2 (Dehmer et al., 1982). However, 
regardless of the findings and conclusion of the study, their results gave an average of 
126 ml/min/m2, not 125 ml/min/m2. So, it still remains a question as to where the 
estimation used originates. The lack of referencing to original work makes this equation 
difficult to evaluate in regard to its ability to estimate VO2, bringing its wide use into 
question. It is unfortunate this equation can be perpetuated without substantial validation.  
The only studies that could be found that used this formula in comparison to 
measured resting VO2 are those performed by Narang et al. (Narang et al., 2012; Narang 
et al., 2014) and are summarized in Figure 2. Again, as mentioned before, the major 
complication of 2012 results is they were obtained prior to performing maximal exercise 
tests and were retrospectively consolidated from two other studies where resting VO2 was 
not a primary variable under consideration. This certainly would affect the findings and 
may not be the most valid design to evaluate the accuracy of a formula to estimate resting 
VO2 during a catheterization procedure. The results from their 2014 report make for a 
better comparison, but regardless they found a significant difference (underestimation) 
between the measured and the estimated VO2 (Narang et al., 2012; Narang et al., 2014). 
Furthermore, they reported a trend of overestimation when resting VO2 was <200 ml/min 
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and an underestimation of VO2  when the measured VO2 was >250 ml/min (Narang et al., 
2012; Narang et al., 2014). Comparing the 2012 and 2014 data, again the effect of the 
methods and patient selection appear to be apparent.  
 
 
 
 
Equation Derived by Bergstra, van Dijk, Hillege, Lie and Mook:   
 
Bergstra et al. divided 310 patients with congenital and acquired heart disease 
undergoing right and left catheterization into a “control group” (n=250) used to develop 
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the prediction equation, and a validation group (n=60) used to validate the equation 
(Bergstra et al., 1995). In their laboratory, the authors note that when an estimation of 
VO2 is needed they use the formulas derived by LaFarge & Miettinen, but find disparity 
when compared to the dye dilution (indocyanine green) method that has been performed 
in their laboratory since the 1960s (Bergstra et al., 1995). They hypothesized that the 
disparity, in part, was due to the fact they more frequently perform catheterization on 
adult patients, where the formula by LaFarge & Miettinen was based primarily on a 
pediatric population (Bergstra et al., 1995). Therefore, they compared 130 patients from 
the control group, matching for the age range used by LaFarge & Miettinen (4-40 years), 
to the equations by LaFarge & Miettinen in order to determine if this was a source of 
error (Bergstra et al., 1995). Similar to Dehmer et al., these authors back-calculated the 
VO2 from the measured cardiac output by the dye dilution method. Therefore, it is 
inherent that they excluded certain patients, including those with atrial fibrillation and 
atrioventricular block (Bergstra et al., 1995). Within their matched control sample of 130 
patients, they found that the estimation by LaFarge & Miettinen underestimated VO2 
when compared to the derived value from the dye dilution method (Figure 1). However, 
from the 230 patients in their control group they developed an estimation equation and 
validated it with the 60 patients in the validation group by comparing the VO2 estimation 
against the dye dilution derived VO2. This demonstrated very good agreement (Figure 3), 
with a mean difference of (dye dilution – estimated) of only 2 ml/min and 95% 
confidence interval of -4 – 8 ml/min (Bergstra et al., 1995).  
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Three studies were found comparing VO2 measured by metabolic gas exchange 
and estimated by the formula of Bergstra et al. (1995), the results of which are 
summarized in Figure 3 (Narang et al., 2012; Narang et al., 2014; Wolf et al., 1998). 
These studies, already described above, have their limitations. Again the study by Wolf et 
al. (1998) was performed with patients including those with HFrEF, but prior to 
cardiopulmonary exercise testing, therefore not sedated (Wolf et al., 1998). The study by 
Narang et al. (2012) was done on obese adults without cardiovascular disease prior to 
cardiopulmonary exercise testing (again not sedated) and in either a standing or seated 
position (Narang et al., 2012). Lastly, the best comparator was the results from Narang et 
al. (2014) as these were done on a clinical population undergoing cardiac catheterization. 
Between these studies (excluding Bergstra et al.), Wolf et al. demonstrated the smallest 
mean difference utilizing a patient group that included patients with HFrEF (similar to 
the patients used by Bergstra et al.) and raises the question of what the results would have 
been if the patients analyzed by Wolf et al. were sedated. However, under the conditions 
presented by Narang et al. (2014), the estimation of Bergstra et al. grossly overestimates 
the resting VO2. The most likely explanation is Bergstra et al. excluded patients with 
valvular heart disease, whereas Narang et al. (2014) included 72% of patients with 
valvular heart disease. Again, patient selection appears to be contributing to these 
findings. 
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Summary of Estimation Equations: 
 
As summarized in Figure 4, all estimation equations appear to under- and 
overestimate the resting VO2. This variability appears to be dependent on patient 
selection, methods for deriving the “measured” VO2 (gas exchange or dye dilution) and 
conditions the measurements are performed. The estimation by LaFarge & Miettinen 
appear to give a larger mean difference than the other measures, but being most studied 
formula it has been tested with the widest variety of patients. However, based on the 
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available literature, it is difficult to develop an appropriate hypothesis of whether 
estimating resting VO2 in patients with HFrEF is appropriate or (if appropriate) which 
estimation equation would provide the “best” estimation. The studies of Kendrick et al. 
and Wolf et al. would suggest that the formulas by LaFarge & Miettinen are likely to 
result in the smallest mean difference in patients with HFrEF. On the other hand, the 
results of Narang et al. (2014) would suggest that it would be the estimation by Dehmer 
et al. Regardless, they all suggest that the mean difference would remain significantly 
different than zero. Even if the mean difference is significantly different than zero, it 
needs to be determined if these differences are clinically significant, that is, should the 
differences found (whether or not statistically different from zero) influence clinical 
decisions?  
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Wolf et al., suggested that an error of >25%, calculated by differences between 
the measured and estimated VO2 divided by the mean of measured and estimated VO2, 
were clinically unacceptably large error (Wolf et al., 1998). Kendrick et al., suggested 
that an error >10% was large enough to potentially err clinically (Kendrick et al., 1988). 
Kendrick et al. based this minimum error on results reported by Selzer and Sudrann 
(1958) that compared two measurements of resting VO2 and two measures of the a-
vO2diff during a cardiac catheterization procedure (Selzer & Sudrann, 1958). However, 
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Selzer also found a 95% confidence interval that approaches 20% error at the upper end 
(Selzer & Sudrann, 1958). Kendrick et al. noted this and estimated a compounding error 
from estimating BSA of ~5% (3-5% has been reported more recently (Verbraecken et al., 
2006)), and subsequently suggested an error >25% as the level where significant clinical 
error would definitely occur (Kendrick et al., 1988). The estimation of VO2 by the 
LaFarge & Miettinen equation resulted in 59% of the patients with >10% error and a total 
of 16% with an error exceeding 25% in the study by Kendrick et al., 25% of the patients 
exceeding 25% error in the study by Wolf et al. and 26% of patients exceeding 25% error 
in the 2014 Narang et al. study (Kendrick et al., 1988; Narang et al., 2014; Wolf et al., 
1998). Although mean differences were significantly different than zero, both Kendrick 
et al. and Wolf et al. reported the lowest mean difference using the LaFarge & Miettinen 
and suggested the use of this equation when measured VO2 results are unavailable or 
suspect, with careful consideration taken concerning this error (Kendrick et al., 1988; 
Wolf et al., 1998). Narang et al. (2014) found the smallest error with the Dehmer et al. 
equation, but concluded that the estimation of VO2 in the calculation of cardiac output 
was inappropriate and did not endorse any of the formulas. Wolf et al. also reported that 
40% of the patients exceeded 25% error when the estimation by Bergstra et al. was used 
and cautioned that this formula should not be used (Wolf et al., 1998). 
Lastly, all the authors of the reported estimation equations (Bergstra et al., 1995; 
Dehmer et al., 1982; LaFarge & Miettinen, 1970), most of the authors of the validation 
studies (Fakler et al., 2005; Kendrick et al., 1988; Narang et al., 2012; Wolf et al., 1998), 
and the authors of clinical practice guidelines and recommendations (Baim & Grossman, 
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2006; Bashore et al., 2001; Summerhill & Baram, 2005) suggest that VO2 should be 
measured and only estimated when error in the measurement is suspected or 
measurement is not possible. Surprisingly, the clinical practice guidelines and 
recommendations suggest the use of the 125*BSA equation, which appears to be the least 
validated (Baim & Grossman, 2006; Bashore et al., 2001; Summerhill & Baram, 2005). 
In patients with HFrEF, it appears the formulas by LaFarge & Miettinen provide the 
lowest mean difference (Kendrick et al., 1988; Wolf et al., 1998), but with potentially 
more than 25% patients having clinically significant error in their estimated VO2 (Narang 
et al., 2014; Wolf et al., 1998). 
Conclusion 
Heart failure represents the final stage of several diseases of the heart and is 
defined as a reduction in the ability of the heart to contract and eject blood (Bui et al., 
2011; Hunt et al., 2009; Lindenfeld et al., 2010). Heart failure represents a major health 
problem, affecting 5.7 million people in the United States, and may be the fastest 
growing cardiovascular disease with an estimated 25% increase in prevalence by 2030 
(Roger et al., 2012). Medicines and cardiac rhythm management devices are used to 
manage HF, but cardiac transplantation remains the only treatment that comes closest to a 
cure. Left ventricular assist device systems are also becoming increasingly more 
advanced and are providing an option beyond the traditional bridge-to-transplant to use as 
destination therapy for those patients who do not qualify for transplantation. For both of 
these therapies, appropriate patient selection is essential in order to provide the patient 
with the best potential outcome and manage limited resources. One of the many 
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measurements used to determine candidacy for these advanced therapies is the cardiac 
output determined during right heart catheterization. The measurement of cardiac output 
is particularly important because it is used to derive several other variables that could 
influence the decision of candidacy and/or the overall management of the patient’s 
syndrome. Though thermal dilution is the most widely used method of determining 
cardiac output in the catheterization laboratory, it has been shown to over-estimate the 
cardiac output in patients with HF, particularly HFrEF. So, it is common practice to 
utilize the Fick method to determine the cardiac output, which requires measurement of 
resting VO2. Though the direct measurement expired gas exchange is the best method 
measuring VO2, estimation equations are most commonly used during right heart 
catheterizations. However, the three most widely used estimation equations have not been 
validated using patients with HFrEF. With potential clinically significant errors >25% in 
the studies that have utilized patients with HFrEF (Narang et al., 2014; Wolf et al., 1998), 
the potential to affect the patient’s candidacy for advanced therapies and/or the patient’s 
subsequent disease management. Therefore, the purpose of this study was to measure the 
resting VO2 in adult patients with HFrEF during right heart catheterization procedures, 
investigate the accuracy of three widely used equations for the estimation of resting VO2 
compared to the direct breath-by-breath measurement of expired air using a metabolic 
cart and determine to what extent clinically significant errors occur using estimation 
equations. 
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CHAPTER III 
METHODS 
The purpose of this study was to measure the resting VO2 in adult patients with 
HFrEF during right heart catheterization procedures, investigate the accuracy of three 
widely used equations for the estimation of resting VO2 compared to the direct breath-by-
breath measurement of expired air using a metabolic cart and determine to what extent 
clinically significant errors occur using estimation equations. 
Participants 
This study was conducted in conjunction with the Advanced Heart Failure 
Program and the LeBauer Cardiovascular Research Foundation at Moses Cone Hospital, 
Greensboro, NC. All study procedures were concurrently approved by the institutional 
review boards of the Cone Health Network and the University of North Carolina at 
Greensboro. All patients provided written informed consent prior to any study-related 
procedures. It was anticipated that up to 54 patients would need to be enrolled in order to 
obtain 44 complete data sets. Forty-eight patients (75% male, age: 63.6 + 11.3 years, 
LVEF: 22 + 6.4%) were enrolled in this study. There was no exclusion based on sex, race 
or ethnicity. All patients scheduled for a right heart catheterization were considered for 
inclusion in this analysis. All patients had a history of a LVEF <40% within the previous 
6 months, with continued signs and symptoms consistent with chronic HF, and had not
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received intravenous inotropic therapy within the previous seven days of the right heart 
catheterization.
Patients were excluded from participating in the study if they had received 
sedation prior to written informed consent being obtained or were otherwise unable to 
provide informed consent (consent was not obtained from healthcare power of attorney). 
Furthermore, patients were excluded if they were determined to have severe lung disease 
(diagnosed as such in the patient’s medical history or, if spirometry data was available, a 
forced expiratory volume in 1 second (FEV1) < 1 L and/or a FEV1 to forced vital capacity 
ratio of < 0.50, or required use of home O2). Patients with significant lung disease 
undergoing right heart catheterization have not been validated with these equations and, 
in the case of this analysis, might have confounded the results. Sedation has been shown 
to reduce resting VO2 (Dehmer et al., 1982) and was used in the development of the three 
equations in question (Bergstra et al., 1995; Dehmer et al., 1982; LaFarge & Miettinen, 
1970). However, heavily sedated patients may not be able to maintain an appropriate seal 
on the mouthpiece and are likely to have difficulty following instructions given to them. 
Therefore, patients were excluded if they were expected to receive more than standard 
sedation (>2 mg of midazolam and/or >50 µg of fentanyl). Due to the limitation of the 
system used to measure the resting VO2, the measurement of gas exchange was not 
possible while the patient was receiving supplemental O2. Therefore, patients were 
excluded if supplemental O2 was expected to be needed after receiving sedation (in those 
who otherwise were not prescribed home supplemental O2). 
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 Once enrolled in the study, it was possible for patients to subsequently receive 
more than standard sedation, require the use of supplemental O2, or withdraw their 
consent to participate. For the current analysis, four patients were withdrawn from the 
study. Two patients required sedation beyond what was considered standard doses 
midazolam (one patient received 4 mg) or fentanyl (one patient received 100 µg). One 
patient became hypoxic during the catheterization procedure and needed supplemental 
O2. Although, the fourth patient had an echocardiogram the week prior to catheterization 
with an LVEF <35%, the operating physician performed a ventriculogram that revealed a 
LVEF of >40% (reported as 40-45%). Therefore, the operating physician and the primary 
investigator decided the patient should be withdrawn. All remaining patients completed 
the 10 minutes of breathing without difficulty or complication. No patient asked to be 
withdrawn once data had been collected.    
Sample Size Justification 
The proposed sample size was estimated using the statistical software, G*Power 
version 3.1 (Faul, Erdfelder, Lang, & Buchner, 2007). Estimation of the sample size 
needed was determined based on the existing literature for each of the three estimation 
equations. Since each of the equations was compared individually, the sample size 
needed to be based on the estimation that requires the most subjects. As can be seen in 
Table 4, the estimation of LaFarge & Miettinen was estimated to require the greatest 
number of patients. To establish the appropriate sample size, the effect size determined in 
Table 4 was used to calculate the sample size at three power levels; 80%, 90% and 95%. 
The results of this analysis can be found in Table 5. From these calculations the 
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enrollment goal was 44 patients completing the resting VO2. Up to a maximum of 54 
patients were expected to be enrolled to ensure that there were 44 complete data sets.   
 
Table 4. Results of Sample Size Estimation for Each of the 
Three Estimation Equations. 
 
  
LaFarge 
& 
Miettinen 
Bergstra 
et al. 
Dehmer 
et al. 
Mean Difference 20.6 21.7 52.9 
Standard Deviation 41.0 29.0 43.2 
Effect Size 0.502 0.748 1.225 
Critical t 2.035 2.120 2.365 
Degrees of freedom 33 16 7 
Sample size 34 17 8 
Actual power 81.1% 82.5% 84.2% 
Two tale t-test of mean difference of single sample. Power 
(1-β) = 80%; α = 0.05 
 
 
Table 5. Results of Sample Size Estimation using Data for 
the Lafarge & Miettinen Estimation Equation. 
 
  Power (1-β) 
  80% 90% 95% 
Critical t 2.035 2.017 2.006 
Degrees of freedom 33 43 53 
Sample size 34 44 54 
Actual power 81.1% 90.3% 95.2% 
Two tale t-test of mean difference of single sample. Effect 
size = 0.502; α = 0.05 
 
Patient Flow through Catheterization Laboratory 
The patient flow through the catheterization laboratory from registration (out-
patient) through entry into the catheterization procedural laboratory was dependent on 
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which laboratory the patient’s procedure was being performed (Main Catheterization 
Laboratory or Joint-Venture Catheterization Laboratory) and if the patient arrived to the 
lab as an in-patient or an out-patient.  
Main Catheterization Laboratory:  
Out-patient (n=7): The patient arrived at Moses Cone Hospital’s Short-Stay 
Center and was registered about 2 hours prior to scheduled procedure. After being 
registered, they were brought to the Short-Stay holding area where the patient changed 
into a hospital gown and the patient’s intravenous lines were started. From the Short-Stay 
Center the patient was transferred to the catheterization laboratory department and taken 
into one of the procedure rooms. Inside the procedure room, the patient was draped and 
the planned insertion area was prepared. When the operating physician arrived, a “time 
out” was performed, where correct patient, procedure and insertion site were confirmed. 
The operating physician evaluated the patient and ordered sedation to be given.  
In-patient (n=9): When ready to perform the patient’s procedure, the 
catheterization laboratory notified the hospital unit where the patient was receiving care. 
The patient was transported from the patient room to the catheterization laboratory. Once 
in the catheterization laboratory, the in-patient process was the same as for the out-
patient. 
Joint-Venture Catheterization Laboratory (n=32): 
The Joint-Venture laboratory performed catheterization procedures on an out-
patient basis only. The patient arrived to the Moses Cone Hospital Heart and Vascular 
Center about 1 hour prior to the procedure and was registered in the waiting area. Once 
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registered, the patient was brought to a holding bay in the Joint-Venture Laboratory, 
allowed to change and was prepared for the procedure. At this point, the process was the 
same as the main catheterization laboratory. 
Data Collection 
Appropriate medical history was obtained in order to determine the patient’s 
candidacy for participation in the study, which included the date and results of the 
patient’s last LVEF measure and the method by which it was obtained (i.e., 
echocardiography, cardiac MRI, ventriculogram, etc.), date and results of the last 
pulmonary function test (if available), co-morbidities (such as lung disease) as listed in 
the patients electronic medical record, a list of currently prescribed medications (as listed 
in the electronic medical record), and results (and date) of the last measure of BNP/Pro-
BNP (if available). Age, sex, height and weight were collected. The results of the 
catheterization were also obtained following the procedure.  
Body surface area, using the patient’s measured height in centimeter and weight 
in kilograms, was calculated according to the formula by Du Bois and Du Bois (Du Bois 
& Du Bois, 1916): 
 
BSA (m2) = 0.007184xweight(kg)0.425xheight(cm)0.725 
 
 
The above estimation of BSA was used in the development of each of the estimation 
equations being investigated (Bergstra et al., 1995; Dehmer et al., 1982; LaFarge & 
Miettinen, 1970) and, therefore, was the only estimation of BSA that could be applied 
when using these formulas. So, despite the reported limitations of this equation, 
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particularly consistently under-estimation of BSA (Haycock et al., 1978; Verbraecken et 
al., 2006), utilizing any other estimation of BSA would have inherently invalidated the 
results of this analysis. 
Resting VO2 was measured utilizing a commercial, open-circuit, breath-by-breath 
gas analysis system (Ultima-CPX, MGC Diagnostics Corp., St. Paul, MN). System 
calibration was performed prior to each study according the manufacturer’s 
specifications. After the completion of the catheterization procedure and while the patient 
remained in the catheterization laboratory procedure room (supine on the laboratory 
table), the patient breathed through a pneumotach attached to a mouthpiece with a nose-
clip occluding nasal ventilation. After a 5-minute run-in phase (to acclimate the patient to 
the mouthpiece and nose-clip), sampling was performed for an additional 5 minutes. 
Utilizing the mouthpiece and nose-clip instead of alternatives such as a facemask or hood 
allowed for the study to more closely replicate that of LaFarge & Miettinen (LaFarge & 
Miettinen, 1970). The other two equations were based on the back calculation of VO2 
from the measurement of cardiac output from dye dilution methods (Bergstra et al., 1995; 
Dehmer et al., 1982), but studies attempting to validate these estimations have used 
expired gas analysis with mouthpiece and nose-clip, as well (Kendrick et al., 1988; 
Narang et al., 2012; Narang et al., 2014; Wolf et al., 1998). Furthermore, the estimation 
equations were developed with patients receiving sedation, while in a supine position and 
in the catheterization laboratory (Bergstra et al., 1995; Dehmer et al., 1982; LaFarge & 
Miettinen, 1970).  
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Estimated resting VO2 was calculated according to each of the three widely used 
empirical formulae:  
1) LaFarge & Miettinen: 
 
 
For males: VO2=(138.1-(11.49*ln(age)*0.378*Heart Rate))*BSA 
 
 
For Females: VO2=(138.1-(17.04*ln(age)*0.378*Heart Rate))*BSA 
 
 
2) Dehmer et al.: 
 
 
VO2=125*BSA 
 
 
3) Bergstra et al.: 
 
 
VO2=(157.3*BSA)+(10*sex[male=1;female=0])-(10.5*ln(age))+4.8 
 
 
Data Analysis 
All statistical analyses and creation of figures were done with JMP Version 10 
(SAS Institute Inc., Cary, NC). With the exception of the mean differences, all 
continuous variables are reported as mean + standard deviation (SD) and categorical 
variables are reported as the total number (percent of total). The mean differences, in the 
context of the Bland-Altman plots are also referred to as biases, are reported as mean + 
standard error (SE).   
 
 
77 
 
Primary Aim 1: 
The results from each empirical formula for estimating resting VO2 were 
compared with the measurement of VO2 with gas exchange. The Bland-Altman method 
(Bland & Altman, 1986) for comparing methods of measuring the same parameter was 
used to assess the agreement between measured and estimated VO2. This method not only 
allows the assessment of agreement, it also allows for the visualization of trends in over- 
or under-estimation of the equations. A common finding in studies evaluating these 
estimation equations in different patient groups have demonstrated trends of 
overestimation with lower resting VO2 (<200 ml/min) and underestimation with VO2 
above 250 ml/min (Bergstra et al., 1995; Fakler et al., 2005; Kendrick et al., 1988; 
Narang et al., 2012). In accordance with this method, the difference of the measured 
minus estimated for each patient was plotted against the corresponding average of the 
measured plus estimated. The limits of agreement will be the mean difference +/- 1.96 
SD. 
Another aspect of the Bland-Altman analysis is to determine bias in the 
measurement, or the mean difference. However, Bland & Altman do not provide any 
recommendation of objectively determining if the bias is significant. A single-sample t-
test was also performed to compare the mean of differences (estimated minus measured), 
or bias, against the hypothetical mean difference of zero, and was considered statistically 
significantly different when p < 0.05. This analysis is consistent with previously 
published research attempting to validate these estimation equations (Bergstra et al., 
1995; Fakler et al., 2005; Kendrick et al., 1988; Narang et al., 2012; Wolf et al., 1998). 
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However, in both studies by Narang et al. absolute mean (Narang et al., 2012) and 
absolute median (Narang et al., 2014) differences were subjected to single-sample t-tests. 
This method ignores the assumption of the Bland-Altman analysis, which suggests the 
results of the method being tested will have some variability above and below zero, or no 
difference (Bland & Altman, 1986).  
Secondary Aim to Aim 1:  
The patients were dichotomized based on select characteristic variables (e.g., sex, 
sedation, and etiology). When dichotomization resulted in two groups of >10 patients 
each, the groups’ measured VO2 was compared utilizing unmatched paired t-tests. When 
measured VO2 between the groups were found to be significantly different, then both 
assessments done for Primary Aim 1 were repeated for this secondary aim.  
Primary Aim 2: 
Although statistical differences are important in clinical research, these 
differences may or may not impact clinical decision-making. Therefore, the question of 
the clinical relevance, or clinical significance, was important to consider. Furthermore, 
statistical significance is often based on the mean with little regard to the individual, but 
clinical significance is often considered at the individual patient level. In order to 
establish if differences between the measured and estimated VO2 were clinically 
significant, the absolute percent error (direction of the error was ignored) in the estimate 
was calculated by dividing absolute difference (estimated - measured) by the mean of the 
measured. Based on previously published data, an absolute percent error exceeding 25% 
was considered clinically significant, and was reported as the percentage of patients at or 
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above 25% error (Bergstra et al., 1995; Narang et al., 2012; Narang et al., 2014; Wolf et 
al., 1998). 
Secondary Aim to Aim 2: 
Another way to consider the clinical significance of differences found between 
measured and estimated VO2 is to consider the impact of these measurements on derived 
variables such as the cardiac index (cardiac output/BSA). The a-vO2diff was collected 
from each patient’s catheterization procedure. This value was used to calculate cardiac 
output and cardiac index based on the Fick equation for the measured and estimated VO2. 
Sensitivity and Specificity determinations were performed for each estimation equation 
(cardiac index based on measured VO2 will be the reference) with three prognostic 
cardiac index cut-off levels: </>2.6 ml/min/m2 (low versus normal), </>2.2 ml/min/m2 
(hypoperfusion versus no hypoperfusion) and </> 1.9 ml/min/m2 (cardiogenic shock 
versus no shock). Sensitivity was computed by the total of the correctly classified patients 
as positive (low, hypoperfusion or cardiogenic shock) divided by the sum of those 
correctly classified as positive (true positive) and those incorrectly classified as negative 
(false negative). Specificity was computed by the total of the correctly classified patients 
as negative (normal, no hypoperfusion or no shock) divided by the sum of those correctly 
classified as negative (true negative) and those incorrectly classified as positive (false 
positive). 
Primary Aim 3 (Exploratory): 
Unlike the other studies that have developed estimation equations for resting VO2, 
this analysis included only patients with HFrEF, making it worthwhile to develop an 
80 
 
empirical equation. If the hypothesis for Aim 1a is supported, stepwise regression 
analysis was performed with a number of covariates (e.g., age, sex, etiology, LVEF, heart 
rate at time of data collection). Covariates were removed from the equation one at a time 
from lowest to greatest significance. Similar to LaFarge & Miettinen (LaFarge & 
Miettinen, 1970), the model was reduced until all remaining covariates were significant at 
p<0.05.
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CHAPTER IV 
RESULTS 
The purpose of this study was to measure the resting VO2 in adult patients with 
HFrEF during right heart catheterization procedures, investigate the accuracy of three 
widely used equations for the estimation of resting VO2 compared to the direct breath-by-
breath measurement of expired air using a metabolic cart and determine to what extent 
clinically significant errors occur using estimation equations. 
Patient Characteristics, Catheterization and Gas Exchange Results 
Patient demographic data for the 44 patients for which gas exchange was 
completed are summarized in Table 6. The average age of the patients was 64.5 + 10.7 
years (range was 34 to 86 years), 65.9% of patients were male, 65.9% were Caucasian, 
65.9% had non-ischemic cardiomyopathies and 47.7% had New York Heart Association 
Class III symptoms. The majority of patients were prescribed beta-blockers, ACE-I/ARB, 
and loop diuretics (Table 7), suggesting the majority of patients was on guideline-
recommended medical therapy. The summary of the pre-catheterization blood labs, right 
heart catheterization results and resting gas exchange results are listed in Tables 8-10.  
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Table 6. Summary of Patient Demographic Data. 
 
    Variable Summary Range 
Gender  
  Female 15 (34.1%) 
 Male 29 (65.9%) 
 Age (years) 64.5 + 10.7 34 - 86  
Race  
  Asian 1 (2.3%) 
 Black/African-American 14 (31.8%) 
 White/Caucasian 29 (65.9%) 
 Body Mass Index (kg/m2) 28.2 + 6.4 18.1 - 46.7 
<25 kg/m2 14 (31.8%) 
 25-29.9 kg/m2 10 (22.7%) 
 >30 kg/m2 20 (45.5%) 
 Body Surface Area (m2) 1.96 + 0.27 1.41 - 2.58 
Heart Failure Etiology 
  Ischemic Cardiomyopathy 15 (34.1%) 
 Non-Ischemic Cardiomyopathy 29 (65.9%) 
 Left Ventricular Ejection Fraction (%) 22.0 + 6.4 10 - 37.5 
New York Heart Association Class 
  II 9 (20.0%) 
 III 21 (47.7%) 
 IIIb 9 (20.0%) 
 IV 5 (11.4%) 
 Diabetes 
  No Diabetes 29 (65.9%) 
 Insulin-Dependent 5 (11.4%) 
 Non-Insulin Dependent 10 (22.7%) 
 Smoking Habit 
  Never Smoked 19 (43.2%) 
 Current Smoker 10 (22.7%) 
 Former Smoker 15 (34.1%) 
 Cardiac Rhythm Management 
  None 21 (47.7%) 
 Cardiac Resynchronization Therapy 5 (11.4%) 
 Implanted Cardioverting Device 16 (36.4%) 
 Pacemaker 2 (4.5%)   
Continuous data presented as mean + standard deviation. Categorical data presented as 
number of patients (percentage of total). 
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Table 7. Summary of Patient Prescribed Heart Failure Medications. 
 
 
  Prescribed 
Not 
Prescribed 
Beta Blocker  34 (77%) 10 (23%) 
Angiotensin Converting Enzyme Inhibitor 24 (55%) 20 (45%) 
Angiotensin Receptor Blocker 12 (27%) 32 (73%) 
Loop Diuretic 31 (70%) 13 (30%) 
Aldosterone Antagonist 14 (32%) 30 (68%) 
Digoxin 7 (16%) 37 (84%) 
Hydralazine 6 (14%) 38 (86%) 
Long-Acting Nitrate 7 (16%) 37 (84%) 
Data presented as number of patients (percentage of total). 
 
Table 8. Summary of Patient Pre-catheterization Blood Labs. 
 
   Variable Summary Range 
Red Blood Cell (Mil/µL) 4.57 + 0.75 2.97 - 7.37 
Hemoglobin (g/dL) 13.2 + 1.6 8.8 - 16.9 
Hematocrit (%) 40.0 + 4.7 27 - 51.6 
Creatinine (mg/dL) 1.34 + 0.81 0.39 - 5.54 
Potassium (mEq/L) 4.2 + 0.6 3.2 - 5.7 
Sodium (mEq/L) 138 + 2 133 - 142 
Carbon Dioxide (mEq/L) 27 + 3 21 - 40 
Calcium (mg/dL) 9.4 + 0.5 8.5 - 10.6 
Blood Urea Nitrogen (mg/dL) 23 + 11 10 - 50 
Glucose (mg/dL) 130 + 66 79 - 407 
Data presented as mean + standard deviation. 
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Table 9. Summary of Results from Right Heart Catheterization Procedure. 
 
  Mean + SD Range 
Systolic Pulmonary Artery Pressure (mm Hg) 45 + 13 10 - 77 
Diastolic Pulmonary Artery Pressure (mm Hg) 20 + 7 7 - 38 
Mean Pulmonary Artery Pressure (mm Hg) 31 + 10 7 - 51 
Pulmonary Capillary Wedge Pressure (mm Hg)* 19 + 8 5 - 36 
Systolic Right Ventricular Pressure (mm Hg) 46 + 11 26 - 77 
Diastolic Right Ventricular Pressure (mm Hg) 7 + 3 -1 - 16 
Systolic Right Atrial Pressure (mm Hg)* 12 + 4 4 - 28 
Diastolic Right Atrial Pressure (mm Hg)† 11 + 5 3 - 28 
Mean Right Atrial Pressure (mm Hg) 9 + 5 1 - 24 
Arterial Saturation (%) 94 + 3 89 - 99 
Venous Saturation (%) 59 + 7 39 - 70 
Arterial Oxygen Content (mL O2/L) 170.1 + 21.3 110.1 - 220.8 
Venous Oxygen Content (mL O2/L) 106.0 + 18.5 59.9 - 152.8 
*Data was not recorded for 2 patients. †Data was not recorded for 1 patient 
 
Table 10. Summary of Gas Exchange Results.  
 
    Mean + SD  Range 
Oxygen Consumption (ml/min) 229.7 + 57.5 142 - 382 
Oxygen Consumption (ml/kg/min) 2.80 + 0.61 1.64 - 4.81 
Respiratory Exchange Ratio 0.82 + 0.07 0.64 - 1.07 
Heart Rate (beats/min) 73 + 12 54 - 105 
Respiratory Rate (breaths/min) 16 + 4 9 - 26 
Tidal Volume (ml) 532 + 224 307 -1620 
Ventilation (L/min) 8.4 + 2.9 4.6 - 17.5 
Partial Pressure of End-Tidal Carbon Dioxide (mm Hg) 33 + 5 22 – 45 
Ventilatory Equivalent for Carbon Dioxide  44.2 + 6.6 30.6 - 58.8 
All ventilatory data was derived from breath-by-breath averaged over last 5 minutes of 
data collection. Heart rate was recorded every 15 seconds and averaged over the last 5 
minutes of data collection. 
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Primary Aim 1 
Figures 5-7 are the Bland-Altman plots of the difference between the estimated 
and the measured VO2. The mean difference and the mean difference + 1.96SD are 
highlighted on each figure. The mean difference is indicative of bias in the estimate and 
the mean difference + 1.96SD provides the limits of agreement. Additionally, a best fit 
linear trend line was added to each plot in order to highlight the trend of overestimation 
of lower VO2 and underestimation of higher VO2. 
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In addition to the above Bland-Altman plots, additional plots were created 
(Figures 8-10) converting the differences between the estimated and the measured VO2 
into percent error of the estimation [(estimated – measured)/measured]. These more 
clearly evaluate the limits of agreement by setting the acceptable limits to +25% of the 
measured VO2. Again, the mean error and limits of agreement are highlighted (red 
dashed lines) as well as the hypothetical mean of 0% error and the acceptable +25% 
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range (black dashed lines). These plots suggest the limits of agreement for each 
estimation equation are too large, as the limits of agreement for the estimation exceed the 
+25% limits. The effect of the overestimation in the measurement of the Dehmer et al. 
and Bergstra et al. estimations (Figures 9 and 10, respectively) becomes prominent in 
these plots.   
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The results of the single-sample t-tests comparing the mean of differences against 
the hypothetical mean difference of zero can be found in Table 11. The estimation 
equations of Dehmer et al. and Bergstra et al. result in a significant overestimation of 
resting VO2 (p<0.05). However, the estimation of LaFarge & Miettinen underestimated 
the resting VO2, but did not reach significance.
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Table 11. Overall and Sub-group Comparisons of the Estimation of Oxygen Consumption by Each of the Estimation Equations and the Measured Oxygen Consumption.
Measured VO2 
+SD      
(ml/min)
Estimated VO2 
+SD      
(ml/min)
Difference    
+ SE (ml/min) p-value
Estimated VO2 
+SD      
(ml/min)
Difference    
+ SE (ml/min) p-value
Estimated VO2 
+SD      
(ml/min)
Difference    
+ SE (ml/min) p-value
Overall group (n=44) 229.7  + 57.5 219.4 + 46.0 -10.3 + 6.2 0.053 245.7 + 34.1 16.0 + 6.4 0.008* 270.3 + 43.8 40.6 + 6.4 <0.001*
Secondary Aim to Aim 1 Sub-Group Analyses
Gender
Male (n=29) 249.9 + 49.1 242.7 + 30.1 -7.2 + 8.2 0.195 256.3 + 27.4 6.4 + 8.2 0.220 283.5 + 35.4 33.6 + 8.5 <0.001*
Female (n=15) 190.6 + 53.3 174.3 + 37.2 -16.3 + 9.2 0.048* 225.1 + 37.2 34.5 + 8.3 <0.001* 244.8 + 48.1 54.2 + 8.3 <0.001*
Pulmonary Hypertension
Yes (n=32) 238.1 + 59.2 226.4 + 43.8 -11.6 + 7.2 0.058 247.7 + 36.3 9.6 + 7.4 0.900 272.9 + 46.8 34.8 + 7.3 <0.001*
No (n=12) 207.3 + 48.0 200.5 + 48.4 -6.8 + 12.9 0.304 240.2 + 28.2 32.8 + 11.7 0.009* 263.4 + 35.3 56.1 + 12.1 <0.001*
Aldosterone Antagonist
Prescribed (n=14) 261.4 + 60.8 236.7 + 35.0 -24.7 + 14.5 0.056 256.6 + 34.5 -4.8 + 14.1 0.369 285.0 + 44.7 23.6 + 14.6 0.065
Not Prescribed (n=30) 214.9 + 50.3 211.3 + 48.8 -3.6 + 6.0 0.276 240.5 + 33.3 25.7 + 6.1 <0.001* 263.1 + 42.3 48.6 + 6.1 <0.001*
Dehmer et al.: VO 2 =125*BSA
Bergstra et al.: (Male) VO 2 =(157.3*body surface area)+10-(10.5*ln(age))+4.8; (Female) VO 2 =(157.3*body surface area)-(10.5*ln(age))+4.8
LaFarge & Miettinen Dehmer et al. Bergstra et al.
Differences were determined by Estimated VO2 - Measured VO2.*significance considered when p<0.05.
LaFarge and Miettinen: (Male) VO 2 =(138.1-(11.49*ln(age)*0.378*HR))*body surface area;  (Female) VO 2 =(138.1-(17.04*ln(age)*0.378*HR))*body surface area
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Secondary Aim to Aim 1 
Patients were dichotomized based on several select characteristics from Tables 6, 
7 and 9. The results of the unmatched pair t-tests of the mean measured VO2 for each 
dichotomization (resulting in >10 patients in each group) can be found in Table 12. As 
can be seen males, patients with pulmonary hypertension, and those prescribed 
aldosterone inhibitors were found to have significantly higher resting VO2 than their 
respective counterpart. 
It was noted in the demographic data that BMI, race, New York Heart Association 
class, smoking habit, diabetes and cardiac rhythm management (presence of a pacemaker 
or ICD) could be stratified into more than two groupings. However, only BMI and 
smoking habit could be divided into sub-groups of at least 10 patients each (Table 13). 
Analysis of variation was performed with no significance found (p>0.05).  
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Measured VO2 
+SD (ml/min)
Mean 
Difference 
+SE (ml/min) p-value
Gender
Male (n=29) 249.9 + 49.1
Female (n=15) 190.6 + 53.3 59.3 + 16.1 <0.001*
Race
White/Caucasian (n=29) 236.6 + 50.6
Non-White/Caucasain (n=15) 216.4 + 68.9 20.2 + 20.1 0.164
Body Mass Index
> 30 kg/m2 240.0 + 58.4
<30 kg/m2 221.1 + 56.5 18.9 + 17.4 0.142
Heart Failure Etiology
Ischemic (n=15) 239.7 + 57.6
Non-Ischemic (n=29) 224.5 + 57.8 15.1 + 18.3 0.208
New York Heart Association Class
II-III (n=30) 228.3 + 53.1
IIIb-IV (n=14) 232.6 + 68.0 -4.3 + 20.6 0.418
Diabetes
No  (n=29) 236.3 + 60.0
Yes (n=15) 216.9 + 51.8 19.4 + 17.4 0.136
Smoking History
Current/Former (n=25) 233.6 + 63.0
Never Smoked (n=19) 224.5 + 50.6 9.2 + 17.1 0.298
Cardiac Rhythm Management
ICD/PPM/CRT (n=23) 239.0 + 60.7
No Device (n=21) 219.5 + 53.3 19.5 + 17.2 0.131
Pulmonary Hypertension
Yes (n=32) 238.1 + 59.2
No (n=12) 207.3 + 48.0 30.7 + 17.4 0.045*
Beta-Blocker
Prescribed (n=34) 227.4 + 53.2
Not Prescribed (n=10) 237.3 + 72.9 -9.9 + 24.8 0.651
Angiotensin Converting Enzyme Inhibitor
Prescribed (n=24) 231.8 + 54.4
Not Prescribed (n=20) 227.2 + 62.3 4.6 + 17.8 0.400
Angiotensin Receptor Blocker
Prescribed (n=12) 238.2 + 71.6
Not Prescribed (n=32) 226.5 + 52.2 11.7 + 22.6 0.307
Loop Diuretic
Prescribed (n=31) 236.9 + 62.7
Not Prescribed (n=13) 212.5 + 39.8 24.3 + 15.8 0.066
Aldosterone Antagonist
Prescribed (n=14) 261.4 + 60.8
Not Prescribed (n=30) 214.9 + 50.3 46.6 + 18.7 0.010*
Dichotmous groups consisting of at least 10 patients per sub-group were selected 
from Tables 6 & 7 (except pulmonary hypertension, which was dervied from 
individual catheterization results). *significance considered when p<0.05.
Table 12. Comparisons of Differences in Measured Oxygen Consumption among 
Dichotomous Groups.
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Table 13. Comparisons of Differences in Measured Oxygen Consumption among 
Grouping Variables with more than Two Sub-groups. 
 
  
Measured VO2 
+SD (ml/min) 
Mean Square 
Difference p-value 
Body Mass Index 
   <25 kg/m2 (n=14) 218.8 + 61.7 
  25-29.9 kg/m2 (n=10) 224.3 + 51.3 
  >30 kg/m2 (n=20) 240.0 + 58.4 2040.5 0.550 
Smoking History 
   Never (n=19) 224.5 + 50.6 
  Current (n=10) 232.9 + 65.3 
  Former (n=15) 234.1 + 63.7 458.1 0.876 
From Tables 6, variables were chosen based on having >10 patients in each sub-
group and could be divided into >2 sub-groups. Significance was considered when 
p<0.05. 
 
Table 11 also contains the individual sub-group results of the paired-sample t-
tests of the differences between the measured VO2 and the estimated VO2 by each 
estimation equation for selected patient characteristics. Males have no significant mean 
difference between the estimated and measured for the LaFarge & Miettinen equation and 
the Dehmer et al. equation, whereas females were found to be significantly 
underestimated by the LaFarge & Miettinen equation (p=0.048) and overestimated by the 
Dehmer et al. equation (p<0.001). The Dehmer et al. equation resulted in a significant 
overestimation in those without pulmonary hypertension (p=0.003). The Dehmer et al. 
equation also resulted in a significant overestimation for those patients not prescribed 
aldosterone antagonist medications (p<0.001). The Bergstra et al. estimations resulted in 
significant mean differences (overestimations) at all levels of dichotomization, except for 
those patients that were prescribed aldosterone antagonist medications (p=0.065).   
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Figures 11-19 are the Bland-Altman plots of the error of each of the estimation 
equations for each dichotomized variable (sex, post-capillary pulmonary hypertension, 
and prescribed aldosterone antagonist). The points and limit of agreement lines are color-
coded for each sub-group within each dichotomous variable. Color-matched range arrows 
were added to highlight the limits of agreement for each sub-group. As can easily be seen 
no sub-group within each variable have limits of agreement contained inside the 
acceptable limits of agreement (black dashed line) of +25% error.  
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Primary Aim 2 
For each of the estimation equations, Figure 20 demonstrates the percentage of 
patients in each of three error categories (<10%, 10-24.9%, and >25%). Only 11.4% of 
patients fall into the >25% error category when using the estimation equation of LaFarge 
& Miettinen. However, the Bergstra et al. equation results in 45% of the patients with 
>25% absolute error in the resting VO2. 
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Secondary Aim to Aim 2 
The actual clinically significant errors in cardiac index for each of the estimation 
equations for various cut-offs can be found in Figures 21-29. All estimation equations 
have >15% of patients with clinically significant error at the cut-off for hypoperfusion 
(<2.2 L/min/m2) and cardiogenic shock (<1.9 L/min/m2). At the highest cut-off of low 
versus normal cardiac index (<2.6 L/min/m2) only the estimation of Bergstra et al. had 
>15% of the patients with clinically significant error.  
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Aim 3 
As described in the methods section, variables were included in the development of 
the estimation equation if they were found to have a significant influence on the resting 
VO2. Table 14 contains an extensive list of continuous variables and the result of linear 
regression analysis. Among these variables the natural log of age was included because of 
its use in both the LaFarge & Miettinen equations and the Bergstra et al. equations. From 
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this list, only BMI, BSA, red blood cell count, systolic RV pressure, mean RV pressure, 
and diastolic right atrial pressure were found to be significantly correlated with measured 
resting VO2 (all p<0.05). Since BMI and BSA are estimations of body size that both 
include height and weight, it was decided to run the regression analysis two times with 
BMI included in one (BSA not entered) and BSA included in the other (BMI not entered) 
to avoid issues of colinearity. Since mean RV pressure includes the measurement of 
systolic RV pressure, and both variables had the same correlation and significance 
(R2=0.11, p=0.027), only the systolic RV pressure was included in the analysis. The three 
dichotomous variables that were evaluated in the secondary aim to Aim 1 above were 
also entered into the analysis. Stepwise regression analysis was performed with these 
covariates utilizing a randomly selected sample of 34 patients. Each covariate was 
removed from the equation one at a time from lowest to greatest significance until the 
remaining covariates were significant at p<0.05. Results of the linear regression modeling 
can be found in Table 15, and the resulting empirical formulas are as follows: 
1) Model 1 (root mean square error = 43.38, adjusted R2 = 0.52, p<0.001): 
 
 
VO2 = -10.76+(127.74*BSA)+(aldosterone antagonist [prescribed=1, not 
prescribed=-1]*22.15) 
 
 
2) Model 2 (root mean square error = 49.35, adjusted R2 = 0.38, p<0.001): 
 
VO2 = 149.4+(sex [male=1, female=-1]*25.41)+(aldosterone antagonist 
[prescribed=1, not prescribed=-1]*28.34) 
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The remaining 10 patients were then used as a test group for each of the resultant 
equations. Table 16 contains the results of the mean difference in the estimated and 
measured resting VO2. Bland-Altman plots of the error in the estimate can be seen in 
Figures 30 and 31.  
 
Table 14. Linear Regression Analysis of Continuous Patient Characteristics. 
 
  Slope R2 adjusted-R2 p-value 
Age (years) -1.4 0.06 0.04 0.099 
Natural Log of Age -85.3 0.07 0.05 0.074 
Heart Rate (beats/min) -0.68 0.02 0.00 0.356 
Body Mass Index (kg/m2) 3.1 0.12 0.10 0.022* 
Body Surface Area (m2) 144.4 0.47 0.46 <0.001* 
Left Ventricular Ejection Fraction (%) -0.02 0.00 -0.02 0.870 
Red Blood Cell (Mil/µL) 23.2 0.09 0.07 0.047* 
Hemoglobin (g/dL) -0.9 0.00 -0.02 0.875 
Hematocrit (%) 0.7 0.00 -0.02 0.703 
Creatinine (mg/dL) 0.1 0.00 -0.02 0.992 
Potassium (mEq/L) -3.9 0.00 -0.02 0.807 
Sodium (mEq/L) -4.4 0.03 0.01 0.248 
Carbon Dioxide (mEq/L) -2.0 0.01 -0.01 0.461 
Calcium (mg/dL) -29.1 0.05 0.03 0.131 
Blood Urea Nitrogen (mg/dL) -0.1 0.00 -0.02 0.873 
Glucose (mg/dL) -0.1 0.02 -0.01 0.417 
Systolic Pulmonary Artery Pressure (mm Hg) 0.9 0.04 0.02 0.166 
Diastolic Pulmonary Artery Pressure (mm Hg) 2.3 0.08 0.06 0.059 
Mean Pulmonary Artery Pressure (mm Hg) 1.4 0.05 0.03 0.130 
Pulmonary Capillary Wedge Pressure (mm Hg) 2.2 0.08 0.06 0.060 
Systolic Right Ventricular Pressure (mm Hg) 1.7 0.11 0.09 0.027* 
Diastolic Right Ventricular Pressure (mm Hg) 2.9 0.03 0.01 0.255 
Mean Right Ventricular Pressure (mm Hg) 3.9 0.11 0.09 0.027* 
Systolic Right Atrial Pressure (mm Hg) 2.5 0.04 0.01 0.220 
Diastolic Right Atrial Pressure (mm Hg) 3.3 0.10 0.07 0.043* 
Mean Right Atrial Pressure (mm Hg) 3.3 0.07 0.05 0.081 
Variables reaching significance (p<0.05) were included into estimation modeling 
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Table 15. Results from Linear Regression Modeling. 
 
  Model 1   Model 2 
  B + SE β p-value   B + SE β p-value 
Body Surface Area (m2) 127.74 + 28.93 0.56 <0.001 
 
-- -- -- 
Not Prescribed Aldosterone 
Antagonist 22.15 + 8.66 -0.33 0.016 
 
-28.34 + 9.57 -0.42 0.006 
Female Gender -- -- -- 
 
-25.41 + 8.98 -0.40 0.008 
Intercept (constant) -10.76 + 58.13 -- 0.854   234.72 + 9.78 -- <0.001 
Model 1 variables entered: Body Surface Area, Pulmonary Hypertension, Gender, Aldosterone 
Antagonist, Diastolic Right Atrial Pressure, Systolic Right Ventricular Pressure, Red Blood Cell Count 
Model 2 variables entered: Body Mass Index, Pulmonary Hypertension, Gender, Aldosterone 
Antagonist, Diastolic Right Atrial Pressure, Systolic Right Ventricular Pressure, Red Blood Cell Count 
B = estimation coefficient, SE = standard error, β = beta coefficient, an indicator of the relative 
impact/importance on the resting oxygen consumption. 
 
 
Table 16. Single-sample t-test Results of the Proposed Models. 
 
  
Measured VO2 +SD      
(ml/min)   
Estimated VO2 +SD      
(ml/min) 
Difference    + SE 
(ml/min) p-value 
Model 1 231.9 + 37.6   242.9 + 36.7 11.0 + 10.7 0.165 
Model 2   244.2 + 42.8 12.4 + 17.5 0.249 
Model 1: VO2 = -10.76+(127.74*BSA)+(aldosterone antagonist [prescribed=1, not prescribed=-
1]*20.33) 
Model 2: VO2 = 234.72+(sex[male=1,female=-1]*25.41)+(aldosterone antagonist 
[prescribed=1, not prescribed=-1]*28.34) 
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CHAPTER V 
DISCUSSION 
The purpose of this study was to investigate the accuracy of three widely used 
equations for the estimation of resting VO2 compared to the direct breath-by-breath 
measurement of expired air using a metabolic cart in an adult population with HFrEF 
undergoing right heart catheterization. 
Aim 1 
This study was designed to accomplish primary and secondary aims. The first aim 
was to compare the differences between the measured resting VO2 and the estimates from 
three commonly used prediction equations (Bergstra et al., 1995; Dehmer et al., 1982; 
LaFarge & Miettinen, 1970). It was hypothesized that each of the estimations would 
result in statistically significant differences compared to the measured VO2. The mean 
difference was found to be significantly different, with significant overestimation, with 
the Dehmer et al. equation (16.0 + 6.4 ml/min, p=0.008) and the Bergstra et al. equations 
(40.6 + 6.4 ml/min, p<0.001). However, the LaFarge & Miettinen equations resulted in a 
non-significant underestimation with a mean difference of -10.3 + 6.2 ml/min (p=0.053). 
The mean difference is a measure of bias in the estimation towards over- or under-
estimating the actually measured VO2. Using a paired-sample t-test provides an objective 
evaluation of the significance the bias differs from 0, or has no bias. However,
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mean difference is only part of fully understanding the differences between the measured 
and estimated VO2.  
Bland-Altman plots reveal information about the mean difference that is not 
apparent in t-tests, which is that all the estimation equations appear to trend towards 
overestimating at lower VO2 and underestimating at higher VO2. This has been a 
consistent finding in all the validation studies performed (Bergstra et al., 1995; Dehmer et 
al., 1982; Kendrick et al., 1988; Narang et al., 2012; Narang et al., 2014; Wolf et al., 
1998). Additionally, it was suggested by Bland & Altman that although some variability 
around the mean difference of 0, the variability should be random without an apparent 
trend in differences across the range of measurements (Bland & Altman, 1986). So, this 
finding alone suggests that the estimation equations do not appropriately estimate resting 
VO2. Furthermore, the plots reveal large ranges in the agreement between the measured 
and estimated VO2. However, in order to better understand the impact of these large 
ranges in agreement, the Bland-Altman plots were reconfigured by dividing the 
difference between the estimated and measured VO2 by the measured VO2 in order to 
obtain percentage of error in the estimation. Aim 2 provided appropriate limits of 
agreement with clinically significant error most likely to occur when the error in the 
estimation reaches 25%. So, limits of agreement ranging from +25% to -25% errors were 
plotted. For the estimations to be truly acceptable, both the positive and negative ranges 
of the mean error + 1.96 SD should be contained within the +25% limits of agreement. In 
all instances, the mean error + 1.96 SD ranges were not contained within the +25% 
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limits. Although this additional analysis was not originally proposed, it was felt to be a 
more novel approach that would fully address the goal of Aim 1. 
A secondary aim to Aim 1 was to begin to explore patient characteristics that may 
have influence on the reliability of the estimation equations. It was proposed to 
dichotomize patients in various sub-groups with a minimum of 10 patients in each group. 
From the demographic data, several appropriate sub-groups were identified and included 
sex, race (white/Caucasian vs. non-white/non-Caucasian), BMI (obese vs. non-obese), 
heart failure etiology (ischemic vs. non-ischemic), New York Heart Association class (II-
III vs. IIIb-IV), diabetes (No diagnoses of diabetes vs. diagnosis of diabetes), smoking 
history (never smoked vs. current/former smoker), cardiac rhythm management (No 
ICD/pacemaker/CRT vs. having ICD/pacemaker/CRT) and whether patients were 
prescribed each beta-blockers, ACEI, angiotensin receptor blockade, loop diuretics, and 
aldosterone antagonists. Additionally, pulmonary hypertension was derived from the 
right heart catheterization data constructed two groups (with and without pulmonary 
hypertension).  
Within these various subgroups, male sex (p<0.001), pulmonary hypertension 
(p=0.045), and being prescribed aldosterone antagonists (p=0.010) all resulted in 
significantly higher measured resting VO2 than their respective counterparts. All previous 
studies that have considered differences between males and females have demonstrated 
higher resting VO2 measurements in men (Bergstra et al., 1995; Dehmer et al., 1982; 
LaFarge & Miettinen, 1970; Narang et al., 2014). The resulting cardiac output was 
compared between men and women to determine if the higher resting VO2 resulted in a 
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higher value. In fact the mean difference and SE were 0.61 + 0.43 L/min (p=0.084) was 
not significantly higher in men.  
Pulmonary hypertension is a common finding among patients with HF, occurring 
in >60% of all (HFpEF and HFrEF) patients with HF (Guazzi & Borlaug, 2012). Despite 
a lack of solid epidemiological evidence, there is likely lower incidence of pulmonary 
hypertension in patients with HFrEF with reported rates of 16-60% demonstrated in 
clinical trials (Guazzi & Galiè, 2012). In addition, the rate was found to be dependent on 
patient selection (Guazzi & Galiè, 2012). The presence of pulmonary hypertension in 
patients with HFrEF indicates more advanced disease and is correlated with worse 
clinical outcomes (Guazzi & Borlaug, 2012; Guazzi & Galiè, 2012). The guidelines for 
determining pulmonary hypertension indicate that all patients with pulmonary 
hypertension have a mean PA pressure >25 mm Hg and those with post-capillary 
pulmonary hypertension (most common form of pulmonary hypertension in patients with 
HF) also have a PCWP >15 (Galiè et al., 2009). In the current study 32 (73%) patients 
were found to have pulmonary hypertension, and among these 28 (64%) patients were 
found to have post-capillary pulmonary hypertension. Again, this raised the question if 
the higher VO2 in those with pulmonary hypertension portended to higher cardiac output. 
The mean differences and SE of 0.07 + 0.39 L/min (p=0.430) clearly indicates there was 
not a benefit to cardiac output from the higher VO2.  
The relationship between aldosterone antagonist prescription and resting VO2 (all 
were prescribed spironolactone) is certainly novel, as these medications were not used in 
the management of HF when any of the estimation equations were developed. 
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Aldosterone antagonist medications are prescribed to patients with severe HF signs and 
symptoms, LVEF <35% and without significant renal dysfunction (Lindenfeld et al., 
2010). Analysis of patient characteristics found that patients prescribed aldosterone 
antagonists were younger (59.6 + 11.8 years) than those not prescribed these medications 
(66.7 + 9.4 years; mean difference 7.2 + 3.6 SE, p=0.03), and there was a greater 
percentage of men in the prescribed group versus the non-prescribed group (86% vs. 
57%, p=0.057). Although age, as a continuous variable, was not found to be significantly 
correlated with resting VO2 in the current analysis, results from other studies of have 
suggested that resting VO2 decreases with age (Bergstra et al., 1995; Dehmer et al., 1982; 
LaFarge & Miettinen, 1970). In at least the limited age-range of the current study, this 
seems to be consistent. It has been suggested that similar to resting VO2, the cardiac 
output decreases with age at ~1% per year (Brandfonbrener et al., 1955). However, the 
comparison of cardiac output between these two groups were not significantly different 
(mean difference 0.43 + 0.42 L/min SE, p=0.160). Men have a significantly higher 
resting VO2 than women, and most certainly the two women in the prescribed aldosterone 
antagonist group are likely having less influence on the mean VO2 of the group than the 
13 women in the non-prescribed group.  It has been shown that older individuals tend to 
have a greater degree of renal dysfunction and older individuals and females are more 
prone to the side-effect of hyperkalemia associated with aldosterone antagonists (Ko et 
al., 2006), which may drive prescription practice toward younger individuals. Although 
not significant, indicators of renal function (creatinine mean difference -0.27 + 0.19 
mg/dL SE, p=0.086; blood urea nitrogen mean difference -4.60 + 3.03 mg/dL SE, 
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p=0.070) suggesting a tendency of patients on aldosterone antagonists to have better renal 
function.  
Within all these grouping variables, the higher resting VO2 did not result in 
significantly higher cardiac outputs. This seems to suggest that within these groups the 
higher VO2 represents a compensatory increase in metabolic work in order to preserve 
cardiac output. Considering the Fick equation of cardiac output = VO2/a-vO2diff, it was 
expected that a-vO2diff would be higher in men vs. women, those with pulmonary 
hypertension versus those without and in those prescribed aldosterone antagonists versus 
not prescribed this medication. However, only patients with pulmonary hypertension 
were found to have significantly higher a-vO2diff than their counterparts (mean 
difference 8.87 + 4.22 mlO2/L SE). Re-working the Fick equation, VO2=heart 
rate*stroke volume [cardiac output]*a-vO2diff, the VO2 could be higher for males and 
those prescribed aldosterone antagonist due to higher heart rate or stroke volume. For 
males, there was no significant difference (males – females) in heart rate (-3.9 + 4.0 bpm 
SE, p=0.170) and stroke volume tended to be higher in males (11.4 + 6.8 ml/beat, 
p=0.053). In those prescribed aldosterone antagonist, heart rate was found to be 
significantly lower (-5.7 + 3.3 bpm SE, p=0.045), but stroke volume was not significantly 
higher in the prescribed group (10.1 + 7.2 ml/beat SE, p=0.085). Although there were 
more males and the patients were younger in the prescribed aldosterone antagonist group, 
further investigation into the results did not yield a clear explanation for the higher 
resting VO2 in this group.        
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Each of the resulting six sub-groups were then subjected to the same analysis as 
performed in primary Aim 1, including paired-sample t-tests and Bland-Altman plots 
(plots utilizing the error were used). The hypothesis for this secondary aim was that all 
differences between the estimated and measured VO2 would remain statistically 
significant. Unfortunately these results failed to support that hypothesis.  
An important aspect of this secondary aim was to explore the sex-specific 
equations of LaFarge & Miettinen and of Bergstra et al. The findings of the current study 
suggest that the female-specific equation for LaFarge & Miettinen resulted in a 
significant difference of underestimating the resting VO2 (p=0.048), where no significant 
difference was found for men (p=0.195). However, both sexes had significant 
overestimation of the VO2 when the Bergstra et al. estimations were used (both p<0.001) 
and reflects the overall poor performance of Bergstra et al. equations. The Dehmer et al. 
estimation does not have sex-specific formulas. It was reported that men had higher 
resting VO2 than women (Dehmer et al., 1982), which is what was found in the current 
study. However, these results suggest the significant mean difference found in the overall 
Dehmer et al. data are being primarily driven by female patients. That is, the mean 
difference between the estimated and measured VO2 for men was 6.4 ml/min (p=0.220), 
where it was 34.5 ml/min (p<0.001) for women. Overall, the results from all three 
equations suggest that a greater number of female patients should be included in the 
development of estimation equations to improve the performance of the estimations. 
Clinically, if these formulas are used, greater consideration should be made of the results 
when used on female patients.    
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The two novel variables of pulmonary hypertension and aldosterone antagonist 
prescription have not been explored by previous research, including the research 
developing the estimation equations. Similar to sex, the estimations of Bergstra et al. 
resulted in significant overestimations regardless of the presence or absence of 
pulmonary hypertension. Where, the Dehmer et al. equation significantly overestimated 
resting VO2 in those without pulmonary hypertension. For the Dehmer et al. and Bergstra 
et al. equations, not being prescribed aldosterone antagonists resulted in significant 
overestimation of the VO2.  Interestingly, with no significant differences found in the 
estimated and measured VO2 for those with or without pulmonary hypertension, or for 
those prescribed or not prescribed aldosterone antagonists, the LaFarge & Miettinen 
equations appear to be resistant to these two variables. The LaFarge & Miettinen equation 
may be resistant to these variables because the equations were developed on a large 
cohort (still largest to date), which likely included patients with pulmonary hypertension 
and accounted for factors such as age (younger) and sex (male) that made up the 
aldosterone antagonist prescribed group.   
Despite whether variables were found to have significant differences or not, the 
Bland-Altman plots of the error demonstrated large variability and poor agreement for 
both sub-groups of each variable. This result is consistent with findings of the primary 
aim that regardless of the significance of the bias of the mean difference, the range of 
error falls outside of the acceptable limits of agreement. 
 
 
130 
 
 
Aim 2 
The second primary aim of the study was to investigate the rate at which each 
equation results in a clinically significant error in resting VO2. This level was chosen 
based on what has been suggested in the literature as being the level at which clinically 
significant error would most likely occur (Kendrick et al., 1988; Wolf et al., 1998). It was 
hypothesized that each of the equations would result in >15% of the patients with >25% 
absolute error. These results do not support this hypothesis. Particularly, the LaFarge & 
Miettinen estimation resulted in 11.4% of patients falling in this category of absolute 
error. In the studies that have performed similar analysis, found that the LaFarge & 
Miettinen had the lowest rates of patients with >25% error (Kendrick et al., 1988; Narang 
et al., 2012; Narang et al., 2014; Wolf et al., 1998). In this sense these results are 
consistent with the literature. When reviewing the Bland-Altman plots of the differences 
or of the error, one can see the 5 patients (11.4%) that fall into this elevated error group. 
Further exploration into the dichotomized Bland-Altman plots there does not appear to be 
a consistent characteristic of these patients with regard to the variables that were found to 
have influence on the results (3 male/2 female, 2 with post-capillary pulmonary 
hypertension/3 without pulmonary hypertension, 2 prescribed aldosterone antagonist/3 
not prescribed aldosterone antagonists). The estimation of Bergstra et al. resulted in 48% 
of the patients with >25% error, which seems to strongly support that these equations are 
inappropriate for use with patients with HFrEF. These results are consistent with previous 
research (Narang et al., 2014; Wolf et al., 1998), which found the highest rate of results 
with >25% error with the Bergstra et al. equations. Also both studies recommended that 
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the Bergstra et al. equations should not be used for any clinical population (Narang et al., 
2014; Wolf et al., 1998). Certainly the findings in the current study support the idea that 
the Bergstra et al. estimation should be avoided. Although these are important, further 
exploration of the true resulting error in a variable derived from the VO2 can provide 
better insight into the real occurrence of clinically significant error. That is, cardiac 
indexes of 1.0 L/min/m2 and 1.26 L/min/m2 (26% difference) would not be considered 
clinically different, yet cardiac indexes of 2.0 L/min/m2 and 2.2 L/min/m2 (10% 
difference) would be clinically different.  
Of course cardiac output (VO2/a-vO2diff) is probably the most obvious variable to 
consider, but the cardiac index (cardiac output/BSA) is clinically more useful. Where 
cardiac output is the measure of the amount of blood that is being circulated every 
minute, the cardiac index of how well the cardiac output is perfusing the body’s tissues. 
So, it may be a more sensitive indicator of cardiac function than the absolute cardiac 
output. In the context of HFrEF, cardiac index is particularly used to help guide treatment 
and determine appropriateness for advanced therapies, such as cardiac transplant or 
LVAD. The secondary aim to Aim 2 essentially plotted the cardiac index using the 
estimated VO2 over the cardiac index derived by the measured VO2. Narang et al. 
performed a similar analysis in a “hypothetical clinical context of aortic valve 
calculations” (Narang et al., 2014), in which the only variable that changed within the 
calculation of the aortic valve area was the individual measure or estimated VO2 (Narang 
et al., 2012; Narang et al., 2014). In these studies, this approach makes sense. 
Specifically, in Narang et al. 2012, the analysis was done prior to exercise tests in 
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patients without heart disease and were absent of any results that would be obtained from 
the right heart catheterization. In Narang et al. 2014, the data were collected during 
clinically indicated right heart catheterizations, but with a broad range of clinical 
indications for undergoing the procedure. Therefore, creating a hypothetical scenario 
homogenized the data for easier analysis. In the current analysis, the patients all had 
HFrEF and the cardiac index was of particular interest in all these patients. So, 
understanding the real clinically significant error provides for more direct clinical 
relevance. At the level of the normal versus abnormal cardiac index (</>2.6 L/min/m2) 
only the estimations of Bergstra et al. had >15% of patients with clinically significant 
error, which further supports the idea of these equations should not be used in HFrEF 
population. Given the idea that majority of patients with HFrEF are found to have 
reduced cardiac index (Carlsson et al., 2012; Cotter et al., 2003), one would really expect 
little error at this level. However, all equations demonstrated >15% of patients with 
clinically significant error at the level of hypoperfusion (<2.2 L/min/m2) and >20% of 
patients with clinically significant error at the level of cardiogenic shock (<1.9 
L/min/m2). Misclassifying patients at these two levels can have significant downstream 
effects. For example, patients that have a cardiac index by the estimation equations >1.9 
L/min/m2, but in reality have a cardiac index <1.9 L/min/m2, may be moved toward 
LVAD implant. However, such patients may be too sick for this advanced therapy and 
would be at high risk for major complications from the procedure. On the other hand, if 
the true cardiac index was used, these patients may be given a round of intravenous (IV) 
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inotropic therapy which could improve the cardiac index and increase the safety of 
implanting the LVAD.  
During the data collection of the study, it was observed that four patients were 
given IV inotrope challenges. During an IV inotrope challenge, patients that are found to 
have a cardiac index substantially <1.9 L/min/m2 during the right heart catheterization are 
given IV infusion of milrinone or dobutamine (milrinone was used in all four instances). 
The infusion is usually staged to find dosing that will demonstrate improvement in 
cardiac index towards 1.9 L/min/m2 or greater. Furthermore, the infusion of inotropic 
medication can also improve (particularly post-capillary) pulmonary hypertension by 
lowering systemic vascular resistance and PCWP (Loh et al., 2001). After each infusion 
dose, the cardiac output (subsequently cardiac index) is measured. Therefore, errors could 
be compounded due to the multiple measures of cardiac output, and (as has been shown 
in the current study) improvements in pulmonary hypertension.  
Aim 3 
The third aim of the study was certainly the most exploratory of the aims and was 
an attempt to develop an empirical formula that may be more specific to patients with 
HFrEF. Several factors were considered in the development of the equations that were 
used in other formulas. Both the LaFarge & Miettinen and the Bergstra et al. formulas 
involved the inclusion of the natural log of age (Bergstra et al., 1995; LaFarge & 
Miettinen, 1970). This variable did not prove to have predictive quality in the current 
analysis. Although the range of patients in the study ranged from 34 to 86 years old, the 
average age in the study was 64.5 years with relatively low standard deviation of +10.7 
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years. Therefore, low variability in this variable likely prevented it from being predictive. 
Bergstra et al. also included heart rate in the calculations, but it also did not predict VO2 
in the current study. Similar to age, heart rate did have a large range (54 to 105 bpm) but, 
again, there was not a great deal of variability (73 +12 bpm). It should be noted that 
LaFarge & Miettinen considered heart rate, and was excluded out of their final model as 
well (LaFarge & Miettinen, 1970).  
As hypothesized, there were novel variables that were found to be significant 
predictors in the multivariate linear regression. These novel variables included BMI, 
pulmonary hypertension, aldosterone antagonist prescription, red blood cell count, 
systolic RV pressure and diastolic RA pressure. Of course, BSA was found to be the 
strongest overall predictor (adjusted R2=0.46, p<0.001) and this is consistent with results 
from all three estimation equations (Bergstra et al., 1995; Dehmer et al., 1982; LaFarge & 
Miettinen, 1970). Sex differences were also consistent findings from the three estimation 
equations as well (Bergstra et al., 1995; Dehmer et al., 1982; LaFarge & Miettinen, 
1970). Although it is not considered in the Dehmer et al. equation, the intention of 
Dehmer et al. was not to produce an estimation equation, but rather to discount the use of 
estimation equations (particularly LaFarge & Miettinen’s) to determine resting VO2 
(Dehmer et al., 1982). 
 Although not as strong as BSA, BMI was found to be predictive. However, this 
was not very surprising since both of these variables are indicators of body size and are 
significantly correlated (R2=0.48, p<0.001). To avoid issues of colinearity, these were not 
entered in the regression modeling at the same time and are the reason two separate 
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models were calculated. For the model in which it was entered BMI was not retained, 
which is likely related to BMI’s limitations. In comparing BSA and BMI further, BSA is 
the stronger predictor likely because it is a better measure of the total cross-sectional area 
metabolic mass, and BSA and BMI are positively correlated because of weight. That is, 
holding height the same, increasing weight increases both BSA and BMI (decreasing 
weight decreases both) and increases the resting VO2 (ml/min). This relationship does not 
hold for height, where maintaining weight constant and increasing height will increase 
BSA, but decrease BMI. So, BMI helps to describe how weight is distributed across 
height, where BSA describes how much tissue there is to be perfused. 
Pulmonary hypertension was another variable that has not surfaced in previous 
estimation equations. However, despite the fact that patients with pulmonary 
hypertension had a significantly higher resting VO2, this dichotomization was not 
retained in either of the equations. This was somewhat surprising in that it had the most 
interesting results in the analyses for the exploratory aim for Aim 1. This variable would 
have set a potential equation apart by tying a marker of clinical severity to estimate 
resting VO2.  
The retention of the aldosterone antagonists into both of the resulting equations is 
certainly novel. As found with the exploration of this variable before, there were a greater 
number of men prescribed these aldosterone antagonists. This may, in part, be driving the 
elevated VO2 in this group. Also, patient selection may have some influence. Within the 
context of the patients selected in the current study, those prescribed aldosterone 
antagonists were younger and absent of significant renal dysfunction. Aldosterone 
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antagonists reverse the action of having elevated circulating aldosterone including; 
reducing volume status, reducing inflammation, and decreasing sympathetic nervous 
system activation (Maron & Leopold, 2010). Although they had a higher average resting 
VO2, there was evidence of decreased activation of the sympathetic nervous system with 
a significantly lower resting heart rate in those prescribed aldosterone antagonists (mean 
difference -5.7 + 3.3 bpm SE, p=0.045). So, while the overall effect of the aldosterone 
antagonists on resting VO2 may be related to the patients prescribed the medication, there 
may be other influences from the action of the medication itself. However, any definitive 
effects if aldosterone inhibition on resting VO2 are unknown at this point.  
The model 2 equations results in patients falling into one of four predicted VO2 
measures; males prescribed aldosterone antagonists = 288.5 ml/min; males not prescribed 
aldosterone antagonists = 231.8 ml/min; females prescribed aldosterone antagonists = 
237.7 ml/min; and females not prescribed aldosterone antagonists = 181.0 ml/min. This 
almost categorical finding significantly limits the ability of the model to accurately 
estimate the VO2 for an individual patient. After all, the range of measured VO2 in the 
current study was 240 ml/min; more than twice 107 ml/min range from Model 2.  Bland-
Altman evaluation of the test group demonstrates a non-significant bias towards 
overestimating resting VO2 and the upper limit of agreement is well above the upper 25% 
error line, which represents the upper limit of agreement.  
Model 1 shares some commonalities with the LaFarge & Miettinen and the 
Bergstra et al. equations. All three of the equations attempt to account for individual 
variability in true resting VO2 by accounting for sex and BSA. Additionally, however, the 
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intercept of the linear regression was included in this model. Without including the 
intercept the model greatly overestimates the resting VO2. Again there does not appear to 
be a significant mean difference in the error with model 1 and the upper limit of 
agreement is just above the upper 25% error limit. Despite this, it may be worthwhile to 
further test this model in future research with a larger sample of patients.  
Conclusion 
This study was not without limitations. First, the sample size was too small to 
fully investigate the findings of the exploratory aim of Aim 1. Furthermore, the sample 
size was too small to adequately build an acceptable estimation equation in Aim 3. 
However, based on the results of previous studies, the study was sufficiently powered to 
compare the estimated and measured VO2 to address the primary Aim 1 and Aim 2. 
Secondly, patients are generally not accustomed to having breathing monitored, 
particularly while breathing through a mouthpiece. This may inherently change the 
patient’s breathing characteristics and influence resting VO2 (Perez & Tobin, 1985). 
However, this is a common method for measuring ventilatory gas exchange and was the 
method utilized by LaFarge & Miettinen (LaFarge & Miettinen, 1970). However, 
compared to the Douglas bag collection of expired gas-exchange performed by LaFarge 
& Miettinen, the measurement of breath-by-breath ventilatory gas exchange by a 
computerized metabolic cart may limit this comparison. However, utilization of 
metabolic carts is more common in modern laboratories, making it more clinically 
applicable. Lastly, due to the limitations of the metabolic cart, gas exchange 
measurement was not possible if any patient was receiving supplemental O2 and patients 
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receiving more than the standard dose of sedation. Therefore these patients were not 
included in the study making the generalization of these results to these patients difficult.  
 The purpose of this study was to measure the resting VO2 in adult patients with 
HFrEF during right heart catheterization procedures, investigate the accuracy of three 
widely used equations for the estimation of resting VO2 compared to the direct breath-by-
breath measurement of expired air using a metabolic cart and determine to what extent 
clinically significant errors occur using estimation equations. Despite the fact that not all 
of the proposed hypotheses were supported by the findings, particularly for Aims 1 and 2, 
the overall conclusion for all three estimations equations argues against the routine use of 
VO2 estimation equations in patients with HFrEF. This is consistent with findings of 
previous literature, particularly that of Narang et al. which evaluated the same three 
estimation equations on large cohorts of non-clinical (Narang et al., 2012) and clinical 
patients (Narang et al., 2014). The results of the secondary aim to Aim 1 suggest that 
certain patient characteristics influence the bias (mean difference) for each of the 
estimation equations, but despite the significance of bias Bland-Altman plots of the error 
indicate limits of agreement outside of what was proposed to be acceptable. Likewise, 
Aim 2 indicates that patients with >25% absolute error occurred at rates of 11%, 23% and 
46% for the LaFarge & Miettinen equation, Dehmer et al. equation and Bergstra et al. 
equation, respectively. Further exploration of the clinically significant error, found that 
the cardiac index derived from the each of estimation equations resulted in >15% with 
clinically significant error at cardiac index thresholds that are most commonly 
encountered in patients with HFrEF.  
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Although this was not the first analysis to evaluate estimation equations in 
exclusively patients with HF, it is the first study to utilize exclusively patients with 
HFrEF during routine right heart catheterization. Therefore, it was important to explore 
the possibility of deriving an empirical equation specific to HFrEF patients. Dehmer et al. 
suggested the large range found in their analysis argues against any empirical formula 
that could reliably estimate resting VO2 across the entire range (Dehmer et al., 1982). In 
fact the range of resting VO2 measured in the current analysis was even larger than that 
found by Dehmer et al. Nonetheless, the use of this specific patient population made the 
endeavor of deriving an empirical formula worthwhile. Two models were developed, and 
immediately Model 2 was dismissed due to the fixed, categorical, nature of the results. 
Model 1, however shared similarities to the estimations of LaFarge & Miettinen and 
Bergstra et al., and initially appeared to provide reasonable results when applied to the 10 
patient test-sample. However, despite insignificant mean differences, the limits of 
agreement fell just outside the acceptable limits. Since the limits were just outside of 
acceptable, it would be interesting to explore the estimation of Model 1 in a larger cohort. 
Furthermore, adding more patients (particularly females) into the development of the 
model may yield an improved, HFrEF-specific estimation.  
In conclusion, the findings from the current study do not support the use of these 
empirical formulae to estimate the resting VO2 in patients with HFrEF undergoing right 
heart catheterization. The direct measurement of the resting VO2 should be the primary 
method applied to the Fick equation for cardiac output. However, if estimations are used, 
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clinicians need to be aware of the significant limitations of these estimations and should 
use caution and good clinical judgment considering administration of advanced therapies.  
 
141 
 
 
REFERENCES 
Abraham, W. T., Young, J. B., Leon, A. R., Adler, S., Bank, A. J., Hall, S. A., . . . on 
behalf of the Multicenter InSync ICD II Study Group. (2004). Effects of Cardiac 
Resynchronization on Disease Progression in Patients With Left Ventricular 
Systolic Dysfunction, an Indication for an Implantable Cardioverter-Defibrillator, 
and Mildly Symptomatic Chronic Heart Failure. Circulation, 110(18), 2864-2868. 
doi: 10.1161/01.cir.0000146336.92331.d1 
Alpert, J. S. (1989). The lessons of history as reflected in the pulmonary capillary wedge 
pressure. J Am Coll Cardiol, 13(4), 830-831. doi: 0735-1097(89)90224-6 [pii] 
Armstrong, L. E., & Costill, D. L. (1985). Variability of respiration and metabolism: 
responses to submaximal cycling and running. Research Quarterly for Exercise 
and Sport, 56(2), 93-96.  
Bahrami, H., Kronmal, R., Bluemke, D. A., Olson, J., Shea, S., Liu, K., . . . Lima, J. A. 
(2008). Differences in the incidence of congestive heart failure by ethnicity: the 
multi-ethnic study of atherosclerosis. Arch Intern Med, 168(19), 2138-2145. doi: 
168/19/2138 [pii]10.1001/archinte.168.19.2138 
 
Baim, D. S., & Grossman, W. (2006). Grossman's cardiac catheterization, angiography, 
and intervention (7th ed.). Philadelphia: Lippincott Williams & Wilkins. 
Bashore, T. M., Bates, E. R., Berger, P. B., Clark, D. A., Cusma, J. T., Dehmer, G. J., . . . 
Documents, A. C. o. C. T. F. o. C. E. C. (2001). American College of 
Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert 
Consensus Document on cardiac catheterization laboratory standards. A report of 
the American College of Cardiology Task Force on Clinical Expert Consensus 
Documents. J Am Coll Cardiol, 37(8), 2170-2214. doi: S0735109701013468 [pii] 
Bergstra, A., van Dijk, R. B., Hillege, H. L., Lie, K. I., & Mook, G. A. (1995). Assumed 
oxygen consumption based on calculation from dye dilution cardiac output: an 
improved formula. Eur Heart J, 16(5), 698-703.  
142 
 
 
Berthelsen, P. G., Eldrup, N., Nilsson, L. B., & Rasmussen, J. P. (2002). Thermodilution 
cardiac output. Acta Anaesthesiologica Scandinavica, 46(9), 1103-1110. doi: 
10.1034/j.1399-6576.2002.460908.x 
Bibbins-Domingo, K., Pletcher, M. J., Lin, F., Vittinghoff, E., Gardin, J. M., Arynchyn, 
A., . . . Hulley, S. B. (2009). Racial differences in incident heart failure among 
young adults. N Engl J Med, 360(12), 1179-1190. doi: 360/12/1179 
[pii]10.1056/NEJMoa0807265 
Bland, J. M., & Altman, D. G. (1986). Statistical methods for assessing agreement 
between two methods of clinical measurement. Lancet, 1(8476), 307-310.  
Bleasdale, R. A., & Frenneaux, M. P. (2002). Prognostic importance of right ventricular 
dysfunction. Heart, 88(4), 323-324.  
Borlaug, B. A., & Redfield, M. M. (2011). Diastolic and systolic heart failure are distinct 
phenotypes within the heart failure spectrum. Circulation, 123(18), 2006-2013; 
discussion 2014. doi: 10.1161/CIRCULATIONAHA.110.954388 
Brandfonbrener, M., Landowne, M., & Shock, N. W. (1955). Changes in cardiac output 
with age. Circulation, 12(4), 557-566.  
Bristow, M. R., Saxon, L. A., Boehmer, J., Krueger, S., Kass, D. A., De Marco, T., . . . 
Feldman, A. M. (2004). Cardiac-resynchronization therapy with or without an 
implantable defibrillator in advanced chronic heart failure. N Engl J Med, 
350(21), 2140-2150. doi: 10.1056/NEJMoa032423350/21/2140 [pii] 
Brooks, G. A., Fahey, T. D., & Baldwin, K. M. (2005). Exercise physiology : human 
bioenergetics and its applications (4th ed.). Boston: McGraw-Hill. 
Bui, A. L., Horwich, T. B., & Fonarow, G. C. (2011). Epidemiology and risk profile of 
heart failure. Nat Rev Cardiol, 8(1), 30-41. doi: nrcardio.2010.165 
[pii]10.1038/nrcardio.2010.165 
Carlsson, M., Andersson, R., Bloch, K. M., Steding-Ehrenborg, K., Mosén, H., Stahlberg, 
F., . . . Arheden, H. (2012). Cardiac output and cardiac index measured with 
cardiovascular magnetic resonance in healthy subjects, elite athletes and patients 
143 
 
 
with congestive heart failure. J Cardiovasc Magn Reson, 14, 51. doi: 
10.1186/1532-429X-14-51 
Clark, A. L., Goode, K., & Cleland, J. G. (2008). The prevalence and incidence of left 
bundle branch block in ambulant patients with chronic heart failure. Eur J Heart 
Fail, 10(7), 696-702. doi: 10.1016/j.ejheart.2008.05.001 
Cotter, G., Moshkovitz, Y., Kaluski, E., Milo, O., Nobikov, Y., Schneeweiss, A., . . . 
Vered, Z. (2003). The role of cardiac power and systemic vascular resistance in 
the pathophysiology and diagnosis of patients with acute congestive heart failure. 
Eur J Heart Fail, 5(4), 443-451.  
de Groote, P., Millaire, A., Foucher-Hossein, C., Nugue, O., Marchandise, X., Ducloux, 
G., & Lablanche, J. M. (1998). Right ventricular ejection fraction is an 
independent predictor of survival in patients with moderate heart failure. J Am 
Coll Cardiol, 32(4), 948-954. doi: S0735-1097(98)00337-4 [pii] 
Dehmer, G. J., Firth, B. G., & Hillis, L. D. (1982). Oxygen consumption in adult patients 
during cardiac catheterization. Clin Cardiol, 5(8), 436-440.  
Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J. J., Ponikowski, P., Poole-
Wilson, P. A., . . . Reviewers, D. (2008). ESC Guidelines for the diagnosis and 
treatment of acute and chronic heart failure 2008: the Task Force for the 
Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the 
European Society of Cardiology. Developed in collaboration with the Heart 
Failure Association of the ESC (HFA) and endorsed by the European Society of 
Intensive Care Medicine (ESICM). Eur Heart J, 29(19), 2388-2442. doi: ehn309 
[pii]10.1093/eurheartj/ehn309 
Doughty, R. N., Whalley, G. A., Gamble, G., MacMahon, S., & Sharpe, N. (1997). Left 
ventricular remodeling with carvedilol in patients with congestive heart failure 
due to ischemic heart disease. Australia-New Zealand Heart Failure Research 
Collaborative Group. J Am Coll Cardiol, 29(5), 1060-1066.  
Du Bois, D., & Du Bois, E. (1916). Clinical Calorimetry. A formula to estimate the 
approximate surface area if height and weight be known. Arch Intern Med, 17, 
863-871.  
144 
 
 
Fakler, U., Pauli, C., Hennig, M., Sebening, W., & Hess, J. (2005). Assumed oxygen 
consumption frequently results in large errors in the determination of cardiac 
output. J Thorac Cardiovasc Surg, 130(2), 272-276. doi: 
10.1016/j.jtcvs.2005.02.048 
Faul, F., Erdfelder, E., Lang, A. G., & Buchner, A. (2007). G*Power 3: a flexible 
statistical power analysis program for the social, behavioral, and biomedical 
sciences. Behav Res Methods, 39(2), 175-191.  
Floras, J. S. (2009). Sympathetic nervous system activation in human heart failure: 
clinical implications of an updated model. J Am Coll Cardiol, 54(5), 375-385. 
doi: 10.1016/j.jacc.2009.03.061 
Galiè, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J. L., Barbera, J. A., . . . 
(CPG), E. C. f. P. G. (2009). Guidelines for the diagnosis and treatment of 
pulmonary hypertension: the Task Force for the Diagnosis and Treatment of 
Pulmonary Hypertension of the European Society of Cardiology (ESC) and the 
European Respiratory Society (ERS), endorsed by the International Society of 
Heart and Lung Transplantation (ISHLT). Eur Heart J, 30(20), 2493-2537. doi: 
10.1093/eurheartj/ehp297 
Ginsberg, F., & Parrillo, J. E. (2009). Cardiogenic shock: a historical perspective. Crit 
Care Clin, 25(1), 103-114, viii. doi: 10.1016/j.ccc.2008.12.005 
Greger, R. (1997). Why do loop diuretics cause hypokalaemia? Nephrol Dial Transplant, 
12(9), 1799-1801.  
Guazzi, M., & Borlaug, B. A. (2012). Pulmonary hypertension due to left heart disease. 
Circulation, 126(8), 975-990. doi: 10.1161/CIRCULATIONAHA.111.085761 
Guazzi, M., & Galiè, N. (2012). Pulmonary hypertension in left heart disease. Eur Respir 
Rev, 21(126), 338-346. doi: 10.1183/09059180.00004612 
Haycock, G. B., Schwartz, G. J., & Wisotsky, D. H. (1978). Geometric method for 
measuring body surface area: a height-weight formula validated in infants, 
children, and adults. J Pediatr, 93(1), 62-66.  
145 
 
 
He, J., Ogden, L. G., Bazzano, L. A., Vupputuri, S., Loria, C., & Whelton, P. K. (2001). 
Risk factors for congestive heart failure in US men and women: NHANES I 
epidemiologic follow-up study. Arch Intern Med, 161(7), 996-1002.  
Heart Failure Society Of America. (2006). HFSA 2006 Comprehensive Heart Failure 
Practice Guideline. J Card Fail, 12(1), e1-2. doi: S1071-9164(05)01361-8 
[pii]10.1016/j.cardfail.2005.11.005 
Hildick-Smith, D. J., Walsh, J. T., & Shapiro, L. M. (2000). Pulmonary capillary wedge 
pressure in mitral stenosis accurately reflects mean left atrial pressure but 
overestimates transmitral gradient. Am J Cardiol, 85(4), 512-515, A511. doi: 
S0002-9149(99)00785-7 [pii] 
Hjalmarson, A., & Fagerberg, B. (2000). MERIT-HF mortality and morbidity data. Basic 
Res Cardiol, 95 Suppl 1, I98-103.  
Huffman, M. D., Berry, J. D., Ning, H., Dyer, A. R., Garside, D. B., Cai, X., . . . Lloyd-
Jones, D. M. (2013). Lifetime risk for heart failure among white and black 
Americans: cardiovascular lifetime risk pooling project. J Am Coll Cardiol, 
61(14), 1510-1517. doi: 10.1016/j.jacc.2013.01.022 
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. 
G., . . . Yancy, C. W. (2009). 2009 focused update incorporated into the 
ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure 
in Adults: a report of the American College of Cardiology Foundation/American 
Heart Association Task Force on Practice Guidelines: developed in collaboration 
with the International Society for Heart and Lung Transplantation. Circulation, 
119(14), e391-479. doi: CIRCULATIONAHA.109.192065 
[pii]10.1161/CIRCULATIONAHA.109.192065 
Just, H. (1996). Pathophysiological targets for beta-blocker therapy in congestive heart 
failure. Eur Heart J, 17 Suppl B, 2-7.  
Kendrick, A. H., West, J., Papouchado, M., & Rozkovec, A. (1988). Direct Fick cardiac 
output: are assumed values of oxygen consumption acceptable? Eur Heart J, 9(3), 
337-342.  
146 
 
 
Kirklin, J. K., Naftel, D. C., Kormos, R. L., Stevenson, L. W., Pagani, F. D., Miller, M. 
A., . . . Young, J. B. (2010). Second INTERMACS annual report: more than 1,000 
primary left ventricular assist device implants. J Heart Lung Transplant, 29(1), 1-
10. doi: 10.1016/j.healun.2009.10.009 
Ko, D. T., Juurlink, D. N., Mamdani, M. M., You, J. J., Wang, J. T., Donovan, L. R., & 
Tu, J. V. (2006). Appropriateness of spironolactone prescribing in heart failure 
patients: a population-based study. J Card Fail, 12(3), 205-210. doi: 
10.1016/j.cardfail.2006.01.003 
LaFarge, C. G., & Miettinen, O. S. (1970). The estimation of oxygen consumption. 
Cardiovasc Res, 4(1), 23-30.  
Lange, R. A., Moore, D. M., Cigarroa, R. G., & Hillis, L. D. (1989). Use of pulmonary 
capillary wedge pressure to assess severity of mitral stenosis: is true left atrial 
pressure needed in this condition? J Am Coll Cardiol, 13(4), 825-831.  
Lechat, P., Packer, M., Chalon, S., Cucherat, M., Arab, T., & Boissel, J. P. (1998). 
Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-
analysis of double-blind, placebo-controlled, randomized trials. Circulation, 
98(12), 1184-1191.  
Lehmann, K. G., & Platt, M. S. (1999). Improved accuracy and precision of 
thermodilution cardiac output measurement using a dual thermistor catheter 
system. J Am Coll Cardiol, 33(3), 883-891. doi: S0735-1097(98)00639-1 [pii] 
Levy, D., Kenchaiah, S., Larson, M. G., Benjamin, E. J., Kupka, M. J., Ho, K. K., . . . 
Vasan, R. S. (2002). Long-term trends in the incidence of and survival with heart 
failure. N Engl J Med, 347(18), 1397-1402. doi: 347/18/1397 
[pii]10.1056/NEJMoa020265 
Lindenfeld, J., Albert, N. M., Boehmer, J. P., Collins, S. P., Ezekowitz, J. A., Givertz, M. 
M., . . . America, H. F. S. o. (2010). HFSA 2010 Comprehensive Heart Failure 
Practice Guideline. J Card Fail, 16(6), e1-194. doi: S1071-9164(10)00173-9 
[pii]10.1016/j.cardfail.2010.04.004 
147 
 
 
Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., . . . 
Stroke Statistics Subcommittee. (2010). Heart Disease and Stroke Statistics--2010 
Update: A Report From the American Heart Association. Circulation, 121(7), 
e46-215. doi: 10.1161/circulationaha.109.192667 
Loh, E., Elkayam, U., Cody, R., Bristow, M., Jaski, B., & Colucci, W. S. (2001). A 
randomized multicenter study comparing the efficacy and safety of intravenous 
milrinone and intravenous nitroglycerin in patients with advanced heart failure. J 
Card Fail, 7(2), 114-121. doi: 10.1054/jcaf.2001.24136 
Maron, B. A., & Leopold, J. A. (2010). Aldosterone receptor antagonists: effective but 
often forgotten. Circulation, 121(7), 934-939. doi: 
10.1161/CIRCULATIONAHA.109.895235 
Mehra, M. R., Kobashigawa, J., Starling, R., Russell, S., Uber, P. A., Parameshwar, J., . . 
. Barr, M. (2006). Listing criteria for heart transplantation: International Society 
for Heart and Lung Transplantation guidelines for the care of cardiac transplant 
candidates--2006. J Heart Lung Transplant, 25(9), 1024-1042. doi: 
10.1016/j.healun.2006.06.008 
Mensah, G. A., & Brown, D. W. (2007). An overview of cardiovascular disease burden in 
the United States. Health Aff (Millwood), 26(1), 38-48. doi: 26/1/38 
[pii]10.1377/hlthaff.26.1.38 
Mohrman, D. E., & Heller, L. J. (2010). Cardiovascular physiology (7th ed.). New York: 
McGraw-Hill, Health Professions Division. 
Morris, N. R., Snyder, E. M., Beck, K. C., Haseler, L. J., Olson, L. J., & Johnson, B. D. 
(2007). The relationship between resting lung-to-lung circulation time and peak 
exercise capacity in chronic heart failure patients. J Card Fail, 13(5), 389-394. 
doi: 10.1016/j.cardfail.2007.02.002 
Moss, A. J. (2003). MADIT-I and MADIT-II. J Cardiovasc Electrophysiol, 14(9 Suppl), 
S96-98.  
Moss, A. J., Hall, W. J., Cannom, D. S., Klein, H., Brown, M. W., Daubert, J. P., . . . 
Investigators, M.-C. T. (2009). Cardiac-resynchronization therapy for the 
148 
 
 
prevention of heart-failure events. N Engl J Med, 361(14), 1329-1338. doi: 
10.1056/NEJMoa0906431 
Narang, N., Gore, M. O., Snell, P. G., Ayers, C. R., Lorenzo, S., Carrick-Ranson, G., . . . 
McGuire, D. K. (2012). Accuracy of estimating resting oxygen uptake and 
implications for hemodynamic assessment. Am J Cardiol, 109(4), 594-598. doi: 
10.1016/j.amjcard.2011.10.010 
Narang, N., Thibodeau, J. T., Levine, B. D., Gore, M. O., Ayers, C. R., Lange, R. A., . . . 
McGuire, D. K. (2014). Inaccuracy of estimated resting oxygen uptake in the 
clinical setting. Circulation, 129(2), 203-210. doi: 
10.1161/CIRCULATIONAHA.113.003334 
Nilsson, L. B., Nilsson, J. C., Skovgaard, L. T., & Berthelsen, P. G. (2004). 
Thermodilution cardiac output – are three injections enough? Acta 
Anaesthesiologica Scandinavica, 48(10), 1322-1327. doi: 10.1111/j.1399-
6576.2004.00514.x 
Nishimura, R. A., Rihal, C. S., Tajik, A. J., & Holmes, D. R. (1994). Accurate 
measurement of the transmitral gradient in patients with mitral stenosis: a 
simultaneous catheterization and Doppler echocardiographic study. J Am Coll 
Cardiol, 24(1), 152-158. doi: 0735-1097(94)90556-8 [pii] 
Novitsky, S., Segal, K. R., Chatr-Aryamontri, B., Guvakov, D., & Katch, V. L. (1995). 
Validity of a new portable indirect calorimeter: the AeroSport TEEM 100. Eur J 
Appl Physiol Occup Physiol, 70(5), 462-467.  
O'Connell, J. B., & Bristow, M. R. (1994). Economic impact of heart failure in the United 
States: time for a different approach. J Heart Lung Transplant, 13(4), S107-112.  
Organ Procurement and Transplantation Network, & Scientific Registry of Transplant 
Recipients. (2012). OPTN/SRTR 2011 Annual Data Report.  Rockville, MD: 
Department of Health and Human Services, Health Resources and Services 
Administration, Healthcare Systems Bureau, Division of Transplantation. 
149 
 
 
Ormiston, T. M., & Salpeter, S. R. (2003). Beta-blocker use in patients with congestive 
heart failure and concomitant obstructive airway disease: moving from myth to 
evidence-based practice. Heart Fail Monit, 4(2), 45-54.  
Packer, M., Fowler, M. B., Roecker, E. B., Coats, A. J., Katus, H. A., Krum, H., . . . 
Group, C. P. R. C. S. C. S. (2002). Effect of carvedilol on the morbidity of 
patients with severe chronic heart failure: results of the carvedilol prospective 
randomized cumulative survival (COPERNICUS) study. Circulation, 106(17), 
2194-2199.  
Perez, W., & Tobin, M. J. (1985). Separation of factors responsible for change in 
breathing pattern induced by instrumentation. J Appl Physiol, 59(5), 1515-1520.  
Pritchett, A. M., & Redfield, M. M. (2002). Beta-blockers: new standard therapy for heart 
failure. Mayo Clin Proc, 77(8), 839-845; quiz 845-836.  
Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., 
. . . Turner, M. B. (2012). Heart Disease and Stroke Statistics—2012 Update. 
Circulation, 125(1), e2-e220. doi: 10.1161/CIR.0b013e31823ac046 
Ross, J. S., Bernheim, S. M., & Drye, E. D. (2011). Expanding the frontier of outcomes 
measurement for public reporting. Circ Cardiovasc Qual Outcomes, 4(1), 11-13. 
doi: 10.1161/CIRCOUTCOMES.110.959908 
Rudolph, A. M., & Cayler, G. G. (1958). Cardiac catheterization in infants and children. 
Pediatr Clin North Am, 5(4), 907-943.  
Selzer, A., & Sudrann, R. B. (1958). Reliability of the determination of cardiac output in 
man by means of the Fick principle. Circ Res, 6(4), 485-490.  
Shenkman, H. J., Pampati, V., Khandelwal, A. K., McKinnon, J., Nori, D., Kaatz, S., . . . 
McCullough, P. A. (2002). Congestive heart failure and QRS duration: 
establishing prognosis study. Chest, 122(2), 528-534.  
Slaughter, M. S., Pagani, F. D., Rogers, J. G., Miller, L. W., Sun, B., Russell, S. D., . . . 
Investigators, H. I. C. (2010). Clinical management of continuous-flow left 
150 
 
 
ventricular assist devices in advanced heart failure. J Heart Lung Transplant, 29(4 
Suppl), S1-39. doi: 10.1016/j.healun.2010.01.011 
Summerhill, E. M., & Baram, M. (2005). Principles of pulmonary artery catheterization 
in the critically ill. Lung, 183(3), 209-219. doi: 10.1007/s00408-004-2537-9 
Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., . . . 
Investigators, A.-A. H. F. T. (2004). Combination of isosorbide dinitrate and 
hydralazine in blacks with heart failure. N Engl J Med, 351(20), 2049-2057. doi: 
10.1056/NEJMoa042934 
Thompson, D. (2010, 9/16/2010). FDA approves devices for heart failure patients. News 
& Events.  Retrieved 11/10/2010, 2010, from 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226123.ht
m 
Towbin, J. A., Lowe, A. M., Colan, S. D., Sleeper, L. A., Orav, E. J., Clunie, S., . . . 
Lipshultz, S. E. (2006). Incidence, causes, and outcomes of dilated 
cardiomyopathy in children. JAMA, 296(15), 1867-1876. doi: 296/15/1867 
[pii]10.1001/jama.296.15.1867 
van Grondelle, A., Ditchey, R. V., Groves, B. M., Wagner, W. W., & Reeves, J. T. 
(1983). Thermodilution method overestimates low cardiac output in humans. 
American Journal of Physiology - Heart and Circulatory Physiology, 245(4), 
H690-H692.  
Verbraecken, J., Van de Heyning, P., De Backer, W., & Van Gaal, L. (2006). Body 
surface area in normal-weight, overweight, and obese adults. A comparison study. 
Metabolism, 55(4), 515-524. doi: 10.1016/j.metabol.2005.11.004 
Voelkel, N. F., Quaife, R. A., Leinwand, L. A., Barst, R. J., McGoon, M. D., Meldrum, 
D. R., . . . National Heart, L. n., and Blood Institute Working Group on Cellular 
and Molecular Mechanisms of Right Heart Failure. (2006). Right ventricular 
function and failure: report of a National Heart, Lung, and Blood Institute 
working group on cellular and molecular mechanisms of right heart failure. 
Circulation, 114(17), 1883-1891. doi: 114/17/1883 
[pii]10.1161/CIRCULATIONAHA.106.632208 
151 
 
 
Wang, Y., Moss, J., & Thisted, R. (1992). Predictors of body surface area. J Clin Anesth, 
4(1), 4-10. doi: 0952-8180(92)90111-D [pii] 
Wolf, A., Pollman, M. J., Trindade, P. T., Fowler, M. B., & Alderman, E. L. (1998). Use 
of assumed versus measured oxygen consumption for the determination of cardiac 
output using the Fick principle. Cathet Cardiovasc Diagn, 43(4), 372-380. doi: 
10.1002/(SICI)1097-0304(199804)43:4<372::AID-CCD3>3.0.CO;2-5 [pii] 
Yancy, C. W. (2004). The prevention of heart failure in minority communities and 
discrepancies in health care delivery systems. Med Clin North Am, 88(5), 1347-
1368, xii-xiii. doi: S0025712504000653 [pii]10.1016/j.mcna.2004.04.015 
Østergaard, M., Nilsson, L. B., Nilsson, J. C., Rasmussen, J. P., & Berthelsen, P. G. 
(2005). Precision of bolus thermodilution cardiac output measurements in patients 
with atrial fibrillation. Acta Anaesthesiologica Scandinavica, 49(3), 366-372. doi: 
10.1111/j.1399-6576.2005.00613.x 
 
 
 
152 
 
